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Man should strive to have his intestines relaxed 
all the days of his life. 
Moses Maimonides, AD 1135 – 1204 
When doctors can not cure an illness 
at least they give it an elegant name 
François de Voltaire, AD 1694 – 1778  
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CD – Cluster of differentiation 
CD4 T-cell – Lymphocyte also called a helper T-cell. 
CD8 T-cell – Lymphocyte also called suppressor/cytotoxic T-cell.  
CFS – Chronic fatigue syndrome 
CF – Chronic fatigue 
CMI – Cellular mediated immunity 
EC-cell – enterochromaffine cell 
FD – functional dyspepsia  
FGID – functional gastrointestinal disorder 
IBS – irritable bowel syndrome 
IBS-D - diarrhea predominant irritable bowel syndrome  
IBS-C - constipation predominant irritable bowel syndrome 
IBS-A - alternating irritable bowel syndrome 
ICF – Idiopathic chronic fatigue 
IFN – Interferon gamma 
MHC class – Major histocompatibility class 
NK cell – natural killer cell 
PBMC – peripheral blood mononuclear cells 
PI-CFS – post-infectious chronic fatigue syndrome 
PI-FGID – post-infectious functional gastrointestinal disorder 
PI-IBS – post-infectious irritable bowel syndrome 
TNF – Tumor necrosis factor alpha 
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1.1 Giardia outbreak in Bergen 
In Norway, Giardia infection is most frequently seen in returning travellers, and testing for this 
parasite is seldomly performed in cases without a travel history. From early October 2004 
there was a two-fold increase in gastroenteritis cases at Bergen legevakt (emergency health 
centre) [1]. At the end of this month an increase was observed in the number of Giardia
positive faecal samples at the laboratory for infectious diseases at Haukeland University 
hospital. The 3rd of November the main newspaper in Bergen brought the news of a Giardia
outbreak. Investigations revealed sewage contamination into Svartediket, an open water 
reservoir supplying water to around 43000 inhabitants in the city centre [2]. A surplus of 2500 
treatments of metronidazole was prescribed during the outbreak period. 1262 outbreak 
related Giardia positive samples were recorded at the laboratory for infectious diseases [3]. 
Especially young adult women aged 20-29 years were affected by the outbreak, most 
probably due to water drinking habits in this group. There were few children and elderly [2].  
1.2 Giardia lamblia and giardiasis 
1.2.1 Giardia biology 
The Giardia species are unicellular flagellated eukaryotic microorganisms found to infect 
many animal species including amphibians, birds and mammals. The species infective to 
humans is called Giardia lamblia (syn. G. intestinalis, G. duodenalis) while the close relative 
G. muris infects mice and is used in research models of the disease [4]. 
G. lamblia is a protozoan parasite with two nuclei, eight flagellae and a unique feature; an 
adhesive disk with which it may adhere to surfaces like the intestinal wall or a cell culture 
tube. It has two major stages in its living cycle, the vegetative trophozoite (figure 1) and a 
relatively inert cyst form. The cyst is the infective form, which in the proximal intestine 
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excysts into the vegetative trophozoite which replicates and lives in the intestinal lumen [5, 
6]. 
Phylogenetic studies have identified seven G. lamblia assemblages (A to G) [7] and 
emerging evidence show variable grades of host specificity.  Genotype A and B are known to 
infect man, with genotype A being the least host 
specific and some degree of zoonotic transmission 
may occur [8]. The relatively large genetic 
differences detected between assemblage A and B, 
suggest they rather should be considered as two 
different species [9]. In Norway genotype A is the 
most prevalent according to a survey of sewage 
influent performed in 2003 [10].  
1.2.2 Clinical presentation and epidemiology 
Giardia lamblia is the aetiological agent of giardiasis and was first observed in 1681 by van 
Leeuwenhoek [11], the inventor of the microscope. Giardia infection may cause acute or 
chronic diarrhea in humans, sometimes with severe disease and malabsorbtion, but may 
also pass unnoticed by the host as an asymptomatic infection [12]. The symptom picture 
commonly include diarrhea, abdominal discomfort, flatulence, nausea, weight loss and 
lassitude [12]. Malabsorbtion of fat and vitamin A [13], as well as vitamin B12 (cobalamin) 
deficiency has been described [14]. In more prolonged, repeated or severe infections, 
malnutrition has been observed [15-17] and sequels in the form of retarded growth and 
development [18, 19] and poor cognitive function [15] have been reported.  
Prevalence rates vary from 2-5% in the industrialized world [20], to 20-30% in developing 
countries, where children are more often infected than adults [21]. The prevalence of Giardia
infection in Denmark, Finland, Norway and Sweden has been estimated to 3% in the 
asymptomatic adult population, and 6% in the population with abdominal symptoms [22]. In 
Figure 1. Giardia lamblia trophozoite
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Norway around 50 persons per year are infected, most of them abroad [23]. In studies from 
industrialised countries like New Zealand and USA [24, 25] the incidence shows a bimodal 
pattern, peaking in the 1-4 
years and 30-40 years age 
groups. The incidence in the 
youngest age group is doubled 
compared the other age 
groups, see figure 2. The para-
site is a commonly identified 
pathogen in waterborne out-
breaks [25] and has a global 
distribution. 
1.2.3 Parasite and host interaction 
Until relatively recently the status of Giardia as a pathogen was disputed [26]. Former 
professor Johs Bøe at Haukeland University hospital were in his PhD dissertation in 1941 
very skeptical towards the pathogenicity of Giardia, but later in 1943 he published 5 pediatric 
cases that had substantially improved after anti-Giardia treatment with atebrine [27]. 
Although Giardia is now recognized as a pathogen that may cause a distinctive disease, the 
underlying mechanisms by which Giardia cause disease is still poorly understood [28]. 
G.lamblia is a lumen dwelling, non-invasive parasite, and giardiasis symptoms may occur 
without overt villous atrophy or other signs of mucosal injury [29, 30]. Giardia infection may 
induce diffuse shortening of epithelial microvilli and this together with reduced disaccharidase 
cause malabsorbtion and maldigestion [31]. In previously infected gerbils the disaccaridase 
deficiencies occur even when rechallenged with only Giardia antigen extracts [32] suggesting 
an immunologic mechanism that was shown to involve CD8 T-cells in mice [33]. In a rat 
model small intestinal injury have been shown to be strain dependent [34]. The parasite may 
     Figure 2. Giardiasis cases (N=58186) in the US between 2006  
     and 2009 by age group and year.  From Yoder et al. 2010
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also induce chloride secretion in human cells [31]. The combination of malabsorbtion of 
sugars, hypersecretion of electrolytes and small intestinal hypermotility [35] are probably the 
most important mechanisms for diarrhea in Giardia infection. 
The pathophysiology in some cases involves disruption of the epithelial tight junctions and 
increased intestinal permeability [36]. In 13 chronic giardiasis cases the loss of epithelial 
barrier function was shown to be due to down regulation of the tight junction protein claudin 1 
and increased enterocyte apoptosis [31]. The resulting increased exposure of any lumen 
antigens, including Giardia antigens, most probably play a role in host immune response and 
symptomatology [28]. 
The large variability of clinical illness is likely to be due to differences both in the parasite and 
host immune responses [37, 38] as well as previous exposure to this pathogen [39]. There 
are no virulence factors or toxins known. A review of studies investigating the association 
between Giardia genotypes and symptomatology show inconsistent results suggesting that 
probably several other factors than genotype are also important for symptom development 
[40]. 
Reports on duodenal inflammation in humans with giardiasis also show variable results. In a 
large Austrian study of 462 patients with Giardia parasites above the duodenal mucosa, only 
3.7% had microscopic duodenitis [29]. Another study found some degree of villous 
shortening or inflammation in 13 out of 17 patients [41]. A study of 32 duodenal biopsies from 
children with giardiasis showed villous atrophy in only one child and no signs of intraepithelial 
lymfocytosis. However, there were 35% showing eosinophilic infiltration and lymph follicle 
formation in the lamina propria [42]. 
1.2.4 Giardia immunity and immune responses 
In most humans, Giardia parasites are usually cleared within few weeks [43]. However, in 
some individuals the infection may persist in immunocompetent individuals [44] who may, or 
may not, have symptoms from the infection. The infection is common and can be persistent 
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in immunological disturbances like common variable immunodeficiency (CVID) [45] or IgA-
deficiency [46]. 
Like many other protozoan parasites G. lamblia possesses the ability to change its surface 
proteins in order to evade its host immune system. By a RNA interference machinery it is 
able to express one variant surface proteins (VSP) at a time from a large repertoire of 
different VSP genes [47, 48].  
In humans, the adult population is less affected than children and specific antibodies against 
Giardia are found in populations in endemic areas [21, 49, 50]. A significantly lower serum 
IgG and IgA has been reported in Indian children with acute and persistent giardiasis, 
whereas asymptomatic carriers had levels comparable to healthy controls [51]. Children with 
persistent giardiasis, despite appropriate chemotherapy, had lower concentrations of Giardia
membrane protein specific antibodies than acute and asymptomatic cases. Thus, the poor 
ability to produce specific anti-Giardia immunoglobulins could be a risk factor for persistent 
giardiasis. 
The host immune responses to acute Giardia infection have mainly been studied in mouse 
models. In mice -TCR-expressing T-cells are required to control infection [52] and CD4 T-
cell depletion results in chronic infection [53]. CD8 T-cells seems not to be important for the 
control of infection in mice, but contribute to the giardiasis related intestinal mucosal injury 
[33]. Important roles have also been shown for mast cells and IL-6 [54], as well as for B-cell 
antibody production [55, 56]. An ex-vivo study of human intestinal lymphocytes stimulated by 
Giardia trophozoites showed importance of IFN-, probably secreted by CD4 T-cells [57]. 
NK-cells do not seem to have a protective role in acute Giardia infection, at least not in mice. 
Beige mice, which are deficient in natural killer cells, cleared Giardia infection equally fast as 
immunocompetent mice [58]. 
Residents in Creston, Canada who were infected in a waterborne Giardia outbreak in 1985 
were significantly less likely to be re-infected during a second outbreak five years later [59]. It 
has also been shown that mice challenged with a second Giardia infection shed far less 
cysts than during the primary infection [60]. When becoming infected with Giardia for the 
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second and third time, fewer Brazilian children had intestinal inflammation measured by 
faecal lactoferrin compared to first time infections [61]. There are therefore strong indications 
that acquired immunity towards this non-invasive lumen dwelling parasite is important for 
protection in many humans. Cellular immunity has previously been described in one case six 
years after infection [62]. 
In summary, predisposition for persistent giardiasis is likely to frequently be due not to a 
single mechanism or host deficiency, but probably to a combination of several minor and 
often unknown or immeasurable anti-Giardia deficiencies interacting with varying degrees of 
acquired immunity in each individual. 
1.2.5 Giardia diagnosis and treatment 
Giardia lamblia was discovered by the inventor of the microscope [11], and microscopy still 
remains an important and widely used method to diagnose giardiasis.  Microscopy of three 
stool samples has a sensitivity of 85-90% [63, 64]. There are also immunochromatographic 
rapid tests with similar sensitivity (81-93.5%) and specificity (<99%) [65, 66]. Alternative 
methods with increased sensitivity and specificity are direct fluorescence microcopy and 
enzyme immunoassay (EIA) kits with close to 100% sensitivity and specificity [67]. 
Polymerase chain reaction (PCR) methods have been mostly used for research purposes, 
but are slowly entering routine diagnostic facilities in large centers, sometimes coupled with 
other common stool parasites [68].  
Treatment of giardiasis is often successful (in 60-90%) with metronidazole [69], a 
nitroimidazole derivate. Alternative drugs include tinidazole, quinacrine, albendazole, 
furazolidone and paromomycin [70]. 
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1.3 Functional gastrointestinal disorders 
1.3.1 Criteria and epidemiology 
A functional gastrointestinal disorder (FGID) is characterized by recurring or chronic 
gastrointestinal symptoms without an identifiable disease process [71]. The disorders are 
hard to classify and early attempts were made in the symptom-based criteria of irritable 
bowel syndrome (IBS) developed by Manning et al for use in differential diagnosis within the 
clinical setting [72]. The more comprehensive Rome process resulted in the first Rome I 
criteria for IBS in 1989, and for the rest of the FGIDs in 1994. The Rome II diagnostic criteria 
which came in 1999 classified the adult FGIDs into oesophageal, gastroduodenal, bowel, 
biliary, anorectal and abdominal pain subcategories, see appendix I [73]. A continuous 
revision process produced a new version of these criteria in 2006 with the Rome III criteria 
[74, 75] subdividing IBS and functional dyspepsia (FD) in new ways. 
The Rome criteria for FGIDs have an important role in standardizing research studies. 
However, a Norwegian study showed a large discrepancy between the criteria and clinical 
practice, where general practitioners diagnosed far less cases as IBS than were positive for 
IBS when completing a Rome II questionnaire. Care should therefore be taken when 
transferring research findings into clinical practice [76]. 
IBS and FD are the most well-known and researched FGIDs. IBS is a common disorder 
characterized by variable abdominal discomfort or pain that occurs in relation to changes in 
defecation frequency or stool consistency and is often relieved by defecation. FD is 
characterized by pain or discomfort in the upper abdomen which is not relieved by, or related 
to changes in stool frequency or form. FD and IBS may both be present in one individual and 
there are indications that IBS and FD share pathophysiological mechanisms, but at different 
sites in the gastrointestinal tract [77].  
The prevalence of IBS has varied from 0.8 to 28% across population studies performed in 
many countries [78]. This large variation is mainly explained by use of different criteria and 
interpretation of these by both investigators and study participants. Adding to this, 
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longitudinal studies have shown that the symptoms of FGIDs are variable over time and may 
change from one FGID disorder to another [79]. A prevalence study using the Rome II 
criteria in 4662 respondents to a mailed questionnaire showed that 8% of Norwegian adults 
had IBS [80]. Food-related gastrointestinal symptoms are common in the general population, 
and often coincides with IBS. A previous study of IBS-patients found that 51% considered 
that their symptoms were linked to individual foods [81], and also improvement following 
exclusion diets have been reported [82]. 
1.3.2 Post-infectious FGIDs 
When the onset of IBS and/or FD is associated with an acute gastrointestinal infection, it is 
often termed post-infectious FD or post-infectious IBS (PI-IBS) [83, 84]. This phenomenon 
was first described by Chaudhary and Truelove in 1962 [85] and has since been shown in 
numerous studies to occur following viral, bacterial and amoebic gastroenteritis and after 
trichinellosis [85-87]. A meta-analysis of PI-IBS estimates that the risk of having IBS one year 
after an acute gastroenteritis is approximately sixfold [88]. Spiller et al summarizes that 
studies of PI-IBS concludes that between 3.7% - 36% of gastroenteritis cases develop IBS 
[84]. 
Between 6 and 17% of IBS patients believe that their symptoms began with an infective 
illness [89]. A large Belgian study with 400 FD patients found 17% to be associated with 
acute infections, ie PI-FD [90]. PI-FD seemed to differ from spontaneous FD by showing 
higher frequency of impaired accommodation, being present in 66% compared with 30% in 
the remainder. Those with PI-FD also reported more weight loss, early satiety, and nausea. 
Dunlop et al also found PI-IBS to differ from spontaneous IBS by a higher frequency of 
diarrhea predominant IBS (D-IBS) and less constipation predominant IBS [91]. 
Severity of initial illness measures like symptom duration and fever, and also young age, 
have been found to be associated with later PI-IBS development [88]. A range of other 
factors such as genetic predisposition for more severe inflammation [92, 93], psychosocial 
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factors like anxiety somatization and negative illness beliefs [94], smoking [95], 
aggressiveness of offending pathogen [96], sex [86] was recently reviewed [84]. Whether 
age [97, 98] and antibiotics [99, 100] are independent risk factors is still not clear. The 
familial aggregation shown in twin studies [101], and the important role for social learning IBS 
[102] seen in spontaneous IBS, is still not studied for PI-IBS. 
One study has found that fewer patients developing PI-IBS had previous treatment for 
anxiety and depression than in non-PI-IBS [91]. However, other studies have found co-
morbidity with anxiety and depression and stressful life events around the time of 
gastroenteritis to be independent risk factors also for development of PI-IBS [88, 103-105]. 
A large study on genetic susceptibility to PI-IBS showed association between three genes; 
TLR9, which encodes a pattern recognition receptor, IL-6, an inflammatory cytokine and 
CDH1 which encodes the tight junction protein cadherin-1, and the development of PI-IBS 
after a large waterborne gastroenteritis outbreak in Walkerton, Canada [106]. The link with a 
cadherin-1, a protein involved in cell barrier function is particularly interesting as a possible 
mechanism in giardiasis-induced IBS because disruption of tight junctions has been 
observed in in vitro models of Giardia infection [107].  
Giardia lamblia infection has not been known to cause PI-IBS before the Bergen outbreak, 
but it is an important differential diagnosis in patients being evaluated for IBS [108], and it 
has also been reported to worsen symptoms in patients with previous IBS [109].  
1.3.3 IBS and low grade inflammation 
A wide range of mechanisms and markers have been investigated to grasp the underlying 
pathophysiology of FGID symptoms precipitation and continuation. In addition to genetic, 
environmental and psychosocial risk factors many studies have examined the roles of 
visceral hypersensitivity, gut motility, intestinal permeability, autonomic nervous system 
dysfunction and bacterial overgrowth. These have been reviewed recently and will not be 
detailed further here [110]. The persistence of, or inability to down regulate, the intestinal 
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inflammatory response is also thought to be an important mechanism behind the 
development of FGID, and interacts with all the above mentioned factors. Perhaps the 
strongest evidence for this is the increased risk of developing IBS after a bacterial 
gastroenteritis shown in several studies [84, 86, 88, 97]. 
Many studies have looked for the underlying markers and mechanisms for this observation, 
and have focused on IBS or PI-IBS. Histological examination of mucosal biopsies has given 
much of the evidence regarding low grade inflammation in IBS. A rare study of full thickness 
jejunal biopsies from IBS patients indicated that inflammation and neuronal degeneration in 
the myenteric plexus were involved in the pathogenesis of IBS [111]. In colonic biopsies of 
77 IBS patients an increased number of lymphocytes have been reported [112]. A 
comprehensive study later showed increased levels of CD3, CD4, CD8 and mast cells in 
biopsies from proximal descending colon of IBS patients [113]. Gastroenteritis patients who 
developed PI-IBS showed persistently high inflammatory cell counts and increased IL-1
expression in rectal biopsies obtained 3 months after the infection compared to patients who 
did not [114]. 
Another study looking at rectal biopsies found EC-cell and T-cell counts to be raised in 
patients with newly developed PI-IBS 3 months after Campylobacter enteritis [115]. The co-
occurrence of EC-cells and T-lymphocytes may be explained by CD4 T-lymphocytes 
stimulating EC-cell hyperplasia and serotonin production via IL-13 [116]. Also, increased 
intraepithelial CD8 T-cells and EC-cells have been reported in rectal biopsies in post 
dysenteric, IBS [117]. NK-cell levels in colonic mucosa in IBS were found to be no different 
than in healthy controls [112]. 
Altered cytokine profiles have been described in IBS and include studies showing elevated 
levels of circulating IL-6 and IL-8 [118-120]. However, Kindt et al did not find altered serum 
IL-6 in 42 FGID patients (including 30 patients with IBS) compared to healthy controls [121]. 
Mucosal mRNA levels of IL-6 have been similar to healthy controls [122] posing the question 
about the source for the elevated IL-6 seen in some studies. Liebregts et al found PBMCs 
from D-IBS patients produced elevated levels of IL-6, IL-1 and TNF [123]. IBS patients has 
18
also been shown to have a have a proinflammatory IL-10/IL-12 ratio (low IL-10 and raised IL-
12) in supernatants from peripheral blood polymorphonuclear cells (PBMC) cultured for 3 
days [124].  
Also genetic studies are pointing towards a role for an altered cytokine profile in IBS patient. 
A significant reduction in the high producer IL-10 genotype frequency has been found in IBS 
patients (21%) compared to controls (32%) [92]. This was not reproduced in another genetic 
study which found that possession of a low producer IL-10 and high producer TNF
genotype was significantly more prevalent in IBS (9%) versus controls (3%) [93]. 
Proinflammatory polymorphisms in the IL-6 and TNF genes were shown to increase the risk 
for IBS in an Iranian study [125]. 
Two studies investigating peripheral blood percentage and concentrations of T and B 
lymphocytes and NK-cells in FGID patient groups have not found these to differ from healthy 
controls [121, 126]. A third study also measured these lymphocyte subsets in IBS patients 
without psychiatric co-morbidity and found no difference compared to controls, even after a 
stressful public talking test [127]. However, two Chinese studies investigating D-IBS report 
differences in CD4/CD8 ratio due to raised CD8 cells [128] or lowered CD4 cells [129]. 
Regarding NK-cells, one study found normal peripheral blood levels of CD56+ NK-cell levels 
in 12 women with IBS compared to 12 women without IBS, but had increased levels of NK-
cells expressing the activation marker CD69 [130]. Another small study has described a post-
prandial decrease in NK-cells and monocytes in IBS patients relative to controls, while 
leukocytes and granulocytes increased [131]. 
Single studies have found increased levels of B-cells expressing IgG or co-stimulatory 
molecules CD80 or CD86 and T-cells expressing 7+HLADR+ and CD69+ in IBS-patients 
compared to controls [126, 132]. Patients with FD have increased levels of peripheral blood 
small intestine homing T-cells expressing both 7-integrin and chemokine receptor 9 (CCR9) 
[133]. Differences in regulatory T-cells have not been found in FGID [134]. 
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1.3.4 FGID and co-morbidity 
The FGIDs are more often than not associated with other functional illnesses as co morbid 
conditions like temporomandibular joint disorder, fibromyalgia and the enigmatic disorder 
chronic fatigue syndrome (CFS) [135]. CFS and FGID shares the characteristic of female 
preponderance, a diagnosis relying on symptom criteria alone and that in many cases the 
onset of symptoms is preceded by an acute infection [84, 136]. 
Fatigue is a common symptom in both FGID and organic gastrointestinal disease [137]. The 
presence of IBS in CFS patients is reported to be between 35%-92% [138-142] while one 
study reports that 14% of IBS patients also have CFS [143]. Whether to regard both 
syndromes, along with multiple other comorbid functional disorders, is a matter of current 
debate [144, 145]. Although researchers of both FGID and CFS are probing hypotheses 
around the same underlying pathophysiological mechanisms regarding immune dysfunction, 
few studies have controlled for the presence of the other condition. A fine exception is the 
study by Scully et al examining 100 IBS patients with different co-morbidities and finding 
higher levels of IL-6 and IL-8 compared to healthy controls. Additionally, the cytokines IL-1
and TNF were found to be increased in several groups with co-morbidity, including the CFS 
group, but not in the 21 IBS patients lacking co-morbidity [120]. In an equally interesting 
study in patients with either Epstein Barr virus (EBV) infection or C.jejuni infection, EBV virus 
infection predicted only short term PI-chronic fatigue (CF), while anxiety and depression  
were stronger predictors for long term PI-CF and CFS. The nature of the infection, 
gastroenteritis, was the strongest predictor of development of PI-IBS. They concluded that 
the impact of anxiety and depression was far less for the development of PI-IBS than for PI-
CFS [144]. 
An anatomic correlate for fatigue in IBS-patients has also been found. An increased coecal 
mucosa cellularity (total number of lymphocytes) correlated with fatigue in a study of 50 IBS 
patient [146]. Coecal mast cells levels have been found to correlate well with both fatigue 
and with depression, suggesting psychological factors are associated with the low-grade 
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inflammatory infiltrate in IBS. However, in another study of rectal mucosa, depression was 
not found to be related to mast-cells, T-lymphocytes or EC-cells [147]. There is clearly a 
complex interplay between psychological, endocrine, immune and neurological factors at 
play in FGID and its various co-morbid conditions. Ongoing research around neuroendocrine 
mediators like corticotropin-releasing factor (CRF) and neuropeptide Y (NPY) might provide 
some answers to this pathophysiological puzzle [148, 149]. 
1.4 Chronic fatigue syndrome  
1.4.1 Criteria and epidemiology 
CFS is a diagnosis of exclusion. Its hallmark symptom is recurrent or persistent fatigue for 
more than 6 months that cannot be explained by specific tests or physical signs. The fatigue 
onset may have a rather abrupt onset, typically with a flu-like illness. The fatigue is 
exacerbated after physical exertion, and patients may need several days to recover to their 
normal fatigued state. Frequently patients also experience concentration and short term 
memory impairments, intolerance to alcohol, headache, dizziness, and myalgias [150]. The 
fatigue may lead to social isolation and decreased ability to work. A number of definitions, or 
sets of criteria, have been developed to further 
define this enigmatic condition for research 
purposes and for clinical use. The CFS criteria pub-
lished in 1994 by Centers for Disease Control and 
prevention (CDC) in Atlanta USA [151] are the most 
widely used in research internationally (figure 3). 
CDC also came up with the term “idiopathic chronic 
fatigue” (ICF) for unexplained chronic fatigue failing 
to meet criteria for the chronic fatigue syndrome 
(see figure 4). 
Figure 4. Conceptual Framework for 
Studying the Chronic Fatigue Syndrome. 
From Fukuda et al. 1994 
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The prevalence of CFS varies widely from 0.007 to 2.8% [152], but a reasonable estimate 
from a large population based study in Wichita, Kansas, USA, states a prevalence of 0.37% 
in women and 0.08% in men [153]. The cause of CFS remains elusive although a many large 
and small studies have reported abnormalities in brain structure and function, 
neuroendocrine responses, sleep architecture, immune function, virological findings, and 
divergent psychological profiles. CFS appears like a combination of predisposing, 
precipitating and perpetuating factors [152]. 
The prognosis of untreated CFS is rather poor. A meta analysis concluded with only 5% of 
patients fully recovering, while around 40% improved during follow-up periods of 1-4 years 
[154]. 
Figure 3  
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1.4.2 Infections and CFS 
Many CFS patients experience flu-like symptoms and feel they get colds frequently. A 
number of infectious agents have been reported to be associated with CFS. These include 
Epstein Barr virus (EBV) (mononucleosis), dengue virus, Ross-river virus and Coxiella 
burnetii (Q fever) [136]. Parvovirus B19 has also been reported to elicit arthralgia and CFS 
[155]. Additional infectious agents implied in CFS development are reviewed by Kerr et al 
and include cytomegalovirus, Brucellae, Toxoplasma gondii, C. burnetii, C. pneumoniae, 
human herpes virus-6(HHV-6), group B coxsackieviruses (CVB), human T cell leukaemia 
virus II-like virus, spumavirus, hepatitis C virus, human lentiviruses and herpes virus-7 [156]. 
One report exists about a possible association between a cluster of 9 fatigue cases in 
Placerville, California and an epidemic of giardiasis [157]. 
Autum 2010 a paper reported xenotropic murine leukemia virus-related virus (XMRV) to be 
present at far higher levels in CFS than in healthy controls [158]. This was considered a 
breakthrough and gave hopes for treatment with anti-retroviral drugs. However, except for 
one report finding another related gammaretrovirus, murine leukemia virus (MLV) [159], a 
row of studies have failed to replicate the findings. Instead, contamination with mouse DNA 
in laboratory reagents has been found to be the likely cause of the association [160]. 
1.4.3 Immunological markers in CFS 
Few studies have been performed regarding the role of immune responses against specific 
infectious agents. Some early reports claimed that differences in the EBV-specific antibody 
responses occurred in individuals developing CFS, but have been shown to be 
unsubstantiated [161]. Analysis of specific humoral immunity in PI-CFS after parvovirus B19 
infection also did not identify any distinguishing pattern [155]. No studies on the role of 
specific CMI towards the suspected eliciting infection have been done in a CFS population. 
Studies regarding differences in the general activation and function in peripheral blood 
lymphocyte subsets have been done since the late 1980ies and have given inconsistent 
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results. Studies until 2002 are excellently reviewed by Natelson et al [162]. Some studies find 
altered NK-cell levels and some find lowered CD4:CD8 ratios, but most studies find normal 
T-, B- and NK cell levels in CFS. HLA-DR expressing CD8 T-cells in CFS have been 
increased in three studies [163-165], while 6 other studies did not find a difference [166-170].  
A Japanese study found significantly reduced NK-cell levels as well as insignificantly 
elevated CD8 levels in both PI-CFS and non-PI-CFS patients [171]. The same groups also 
showed the NK-cells levels to return to normal after successful recovery in the PI-CFS group 
[172]. 
The most consistent immunological deficit measured in CFS is decreased NK cell 
cytotoxicity. A more recent study have also found CD8 cell cytotoxicity to be decreased and a 
decrease in the CD56brightCD16neg NK-cell subset and increased CD4CD25FoxP3 
regulatory T-cells in CSF has been reported [173]. Elevated CD26 expression on T-cells and 
NK-cells (marked with CD2) has been put forward as a promising biomarker in CFS [174]. 
Some caution needs to be taken regarding these measurements, as NK-cell cytotoxicity is 
also negatively influenced by chronic stress like unemployment [175]. NK-cells are also 
influenced by sleep and depression [176] and are known to fluctuate considerably with 
exercise. However, resting NK-cell levels are not much different in athletes compared to non-
athletes [177]. A review article on depression and stressors relationship with immunological 
assays concluded “in both major depression and naturally occurring stressors the following 
effects are shared: leukocytosis, increased CD4/CD8 ratios, reduced proliferative response 
to mitogen, and reduced NK cell cytotoxicity” [178]. Given the relatively frequent co-morbidity 
with psychiatric illness and life stressors in CFS it is therefore necessary to record and 
evaluate this co-morbidity in future studies, and plan studies in such ways that stressors 
before and around blood sampling are avoided or standardized for all participants. 
24
2. AIMS OF THE STUDY 
The main aims of this study were: 
• To describe symptoms, duodenal biopsies and other clinical findings in 
patients with persistent abdominal symptoms after Giardia infection. 
• Characterize and classify the observed post-giardiasis abdominal symptoms 
into internationally recognized categories of FGID 
• To investigate persistence of specific cell mediated immunity against 
giardiasis, and evaluate its role as a possible risk factor for developing post-
giardiasis chronic fatigue syndrome and functional gastrointestinal disease. 
• To evaluate peripheral blood lymphocyte subsets reported as markers of 
immune dysfunction in Giardia induced post-infectious functional 
gastrointestinal disorders and chronic fatigue syndrome 
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3. MATERIALS AND METHODS 
3.1 Study population 
The study populations of the studies included in this dissertation are illustrated in figure 5. 
Participants are drawn from a cohort of patients exposed to Giardia infection who were 
examined at various time points later due to persisting gastrointestinal symptoms (I, II) 
fatigue symptoms (IV) or because of their past Giardia exposure (III). A small Giardia
exposed, rapidly recovered control group was used for symptom comparison in study I. 
Except the unexposed controls in study III and IV, all study populations included in these 
studies had confirmed Giardia infection during the outbreak. Knowingly, we thereby excluded 
a number of referred patients who were exposed to contaminated water, had gastroenteritis 
Figure 5. Giardia cohort populations included in the four papers of this dissertation.  
* All individuals with laboratory confirmed Giardia infection received the questionnaire after three years,
including the patient and control groups evaluated in the Study I and II. 
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during the outbreak and therefore were likely to have the same condition, but did not have 
laboratory confirmed Giardia. This was done to be as certain as possible about the role of 
Giardia infection in the studies performed. 
The patient groups, and therefore also the matched control groups, were predominantly adult 
women with mean age range 31.8 - 42.4 years in the four studies. The percentage of 
females ranged from 61.3 - 79.0%. The female preponderance most probably was due a 
higher attack rate of the outbreak infection in adult females due to water drinking habits [2]. 
3.2  Diagnostic criteria and symptom scoring 
FGID classification – Patients were given a questionnaire with a selection of questions to 
diagnose FD and the functional bowel disorders by the Rome II criteria [73]. All FGID 
diagnoses require the absence of specific organic disease that may explain the symptoms, 
including upper endoscopy to diagnose FD. We used the Rome II criteria in the first two 
studies and therefore continued with these criteria in new studies also after the arrival of 
Rome III criteria. 
IBS - At least 12 weeks, which need not be consecutive, in the preceding 12 months of  
abdominal discomfort or pain that has two of three features: 
- relieved with defecation 
- onset associated with a change in frequency of stool 
- onset associated with a change in form (appearance) of stool 
FD -  At least 12 weeks, which need not be consecutive, in the preceding 12 months of: 
- Persistent or recurrent symptoms (pain or discomfort in the upper abdomen) 
- No evidence that dyspepsia is exclusively relieved by defecation or associated 
with the onset of a change in stool frequency or stool form (i.e., not IBS). 
Based on the dominant symptom features IBS can be further subdivided into diarrhea 
predominant IBS (D-IBS), alternating IBS (A-IBS) and constipation predominant (C-IBS).A 
detailed description of these IBS subgroups can be found in study II. Patients with prolonged 
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abdominal symptoms fulfilling neither FD nor IBS criteria were grouped as other FGID 
including functional abdominal pain, functional diarrhoea, functional bloating and unspecified 
functional bowel disorder in study II and IV. It is hard for most people to remember and 
evaluate their abdominal complaints throughout the last 12 months. A more practical 
timeframe is therefore often used for research purposes, and was also used in our study 
asking about any abdominal complaint during the last 12 weeks that were present at least 
one day per week for 3 out of the 12 weeks [80]. 
Abdominal symptoms - The ordinal scale developed by Kane et al [179] quantifying the 
subjective severity of nausea, abdominal pain, boating, constipation and anorexia had been 
used in the study population almost from the start. The scale grades all the mentioned 
symptoms from 0 - 10 with 0 = no symptoms and 10 = severe symptoms. 
CFS - CFS and also ICF were clinically diagnosed according to the Fukuda criteria [151] 
(figure 2) after a thorough work-up involving consultations with specialists in 
neurology, psychiatry and internal medicine, routine and clinically indicated blood 
tests and a magnetic resonance imaging brain scan. 
Fatigue symptoms - In study IV we used the validated Fatigue Questionnaire (FQ) [180] 
which consists of 11 questions addressing different aspects of fatigue. To each question 
there are four possible answers (“less than normal”, “as normal”, “more than normal”, “much 
more than normal”) that are scored (0, 1, 2, 3) and added to give a total fatigue score (range 
0 to 33). The form has been used previously in a study on fatigue in the general population in 
Norway [181]. Based on this form one may define “Chronic fatigue” as an added fatigue 
questionnaire score above four when using a dicotomised score of the 11 questions in the 
fatigue questionnaire (0 and 1 into 0, 2 and 3 into 1), provided fatigue had been present for at 
least the last six months. 
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3.3  Systematic routine examinations 
The department of histology performed routine evaluation of all duodenal biopsies. Distal 
duodenal biopsies were evaluated by an experienced pathologist blinded to other clinical 
information about the patients. Biopsy results were divided into three groups: normal 
histology (grade 0), mild pathology (grade 1) and moderate to severe pathology (grade 2) 
based on the description. Detailed description can be found in paper I. 
Blood samples in the work-up and clinical evaluations in Study I and IV were performed at 
the hospital routine laboratories and included electrolytes, haematology, hormones, 
immunoglobulins, anti-endomysial and anti-tissue transglutaminase, Giardia rapid 
immunochromatographic test (ImmunoCardSTAT! Cryptosporidium/Giardia rapid assay; 
Meridian Bioscience) and microscopy of three stool samples after concentration by formalin-
ether concentration technique. In study III & IV we had established a 18S Giardia PCR [182] 
to rule out giardiasis based on one stool sample. 
Faecal calprotectin, a marker of intestinal inflammation [183], was analysed by the ELISA-
based φhiCal Test (NovaTec Immundiagnostica GmbH, Germany) as part of hospital routine 
work. Faecal samples were also cultured for the presence of pathogenic bacteria in Study I. 
3.4 Immunological methods 
3.4.1 Mononuclear cell isolation and culture 
Blood samples were drawn in the morning in BD Vacutainer Na-citrate CPT tubes. These 
tubes enabeled isolation of peripheral blood mononuclear cells (PBMC) by direct density 
gradient separation. PBMC were washed twice in PBS with 1% bovine serum albumin before 
being stained for flow cytometric analysis. PBMCs were cultured in 96-well U-bottom 
microtiter plates in X-vivo 15 medium supplemented with L-glutamin, gentamicin and phenol 
red (figure 6). Cells were cultured in the presence of Giardia antigens, control antigens or 
medium alone for 6 days at 37ºC in a humidified atmosphere of 5% CO2. All cultures were 
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prepared in triplicates. Preparation of Giardia parasite antigens is described in detail in paper 
III.
3.4.2 Tritiated thymidine incorporation assay 
This assay is a widely used and robust way of 
measuring T-cell proliferation. The incorp-
oration of 3H thymidine in newly synthesized 
DNA gives a measure for the cellular 
proliferative responses [184]. By stimulating 
cells with the antigen of interest one can then 
measure the T-cell responses towards that 
antigen, as a measure of antigen specific cell 
mediated immunity (CMI). It provides information about the total amount of newly 
synthesized DNA, but it does not reveal anything about the phenotype of the cells 
proliferating. 
We cultured the cells for 5 days and then the PBMC were pulsed with 37kBq/well of 3H-
thymidine and harvested 18 hours later onto glass-fibre pads. Radioactivity was determined 
by liquid scintillation counting in a β-counter. Proliferation was determined as counts per 
minute. Assay results were expressed as stimulation indices (SI) where responses in 
stimulated cells were divided by the response for corresponding unstimulated cells. 
3.4.3 Flow cytometry assay 
A flow cytometer is an instrument identifying cells and other particles passing individually 
through a narrow tube. Cells are illuminated by a laser beam, enabling cellular characteristics 
like size and granularity to be recorded, as well as the light emitted from fluorescent dye 
markers tied to the cellular molecules of interest. Combining many antibody linked dyes 
Figure 6. Cells were cultured in triplicates in 
96-well plates for both flow cytometry and 
proliferation assays 
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enables detailed phenotyping of cells 
but need careful planning: Strength of 
the fluorescent dyes used, amount of 
target molecules on cells and comp-
ensation of interfering dyes are 
important factors for successful mea-
surements. When properly set up the 
method can provide detailed inform-
ation about specific CMI towards viral 
and bacterial antigens by staining for 
molecules expressed on the surface of activated or proliferating cells [185-188]. 
We used a Beckman Coulter Cytomics FC 500 MPL flow cytometer to analyse surface 
markers on CD4 and CD8 T-cells including the late activation markers HLA-DR and CD25 
and the recall antigen activation marker CD26, as well as the memory cell marker CD45RO 
(figure 7). Assessment of surface markers is easy to perform since cells can be stained in a 
single procedure without permeabilization of cells. There are also some limitations, for 
example that some markers may be non-specifically upregulated, can also be expressed on 
resting cells (like CD25), or have high baseline levels. 
Lymphocyte subpopulation quantification was performed using the hospital routine laboratory 
equipment; a BD Multitest 6-color TBNK kit with BD Trucount Tubes for relative and absolute 
concentration determination. Full blood samples were analysed, after erythrocyte lysis, on a 
BD Canto II flow cytometer. 
3.4.4 Other methods for measuring CMI 
In the planning of Study III and IV, other methods for measuring CMI were also evaluated. 
Identification of proliferating cells is possible by flow cytometric analysis after staining  
cultured cells with bromodeoxyuridine (BrdU) or Carboxyfluorescein Succinimidyl Ester 
Figure 7. Plot showing CD4 T-cells expressing activation 
markers CD45RO and HLA-DR and gate for determining the 
percentage of cells positive for both markers. 
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(CFSE). Incorporation in DNA of the thymidine-analogue BrdU is an option whereby an 
antibody against BrdU can later be used to identify proliferating cell subsets [189]. However, 
this assay is labor intensive and can be unstable. Staining with the fluorescent dye CFSE is 
another way to follow proliferating cells as this dye is divided between daughter cells, who 
then stain less strongly, and can thereby reveal the number of cell divisions that have 
occurred in specific cell populations [190]. The assay is capable of simultaneously evaluating 
proliferation and phenotype of antigen responsive T-cell clones. It would have been used in 
Study III and IV if it had been established in our laboratory at the time of these experiments.  
Methods avoiding cell stimulation and culture are also available as antigen specific T-cells 
can be visualized by fluorescently labeled, multimeric peptide-MHC complex that binds to the 
corresponding specific T-cell receptor if they are present in a patient sample. Tetramers are 
available both for MHC class I and II enabling analysis of antigen specific CD8 and CD4 cells 
and to further enumerate, characterize and purify these cells [191]. Disadvantages of this 
technique includes need for previous knowledge of each subjects HLA haplotype (and 
availability of the corresponding tetramer), and knowledge of a specific and well-working 
antigenic peptide. Tetramers do not separate between anergic and activated antigen specific 
T-cells [192].
A different approach would have been to measure and analyze the cytokine profiles in 
supernatants above antigen stimulated cells [193]. This method enables a better evaluation 
of the quality of the response towards the stimulating antigen, but not which cells are 
contributing to the production of these cytokines. This can, however, be achieved by 
intracellular cytokine staining followed by flow cytometric analysis. The method requires 
culture of stimulated cells in the prescence of a protein transport inhibitor, fixation and 
permeabilization of the cell to allow entry of the fluorescent antibodies targeting key 
intracellular cytokines like TNF and IFN [194]. The method is labour intensive and not all 
cytokines are stably measured by this method. Cytokine secreting cells can also be 
measured with high sensitivity by enzyme-linked immunospot (ELISpot) following antigen 
stimulation [195].  
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3.5 Ethics 
All studies were approved by the Regional Committee for Medical Research Ethics and 
conducted according to the Declaration of Helsinki. The Norwegian Social Science Data 
Services approved the data collection and protection. 
3.6 Statistical analysis 
Fisher's exact test was used for testing categorical variables while Mann-Whitney's test was 
used for comparing continuous variables as they sometimes did not show a satisfactory 
normal distribution. Kruskal-Wallis test was used to analyse differences in non-parametric 
variables over more than two groups. In study IV we used linear regression for the correlation 
between NK-cell levels and symptoms. SPSS versions 14 – 18 were used for all statistical 
analyses. 
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4. SUMMARY OF PAPERS 
The first two studies included work-up and follow-up of referred patients during the first two 
years after the outbreak, while the latter two studies examines long-term cellular immune 
responses and immune dysfunction markers five years after the outbreak in the whole 
population of Giardia outbreak exposed individuals who did or did not report fatigue in a 
mailed questionnaire three years after the outbreak. 
Paper I:  Persisting symptoms and duodenal inflammation related to Giardia 
duodenalis infections. 
The study describes findings of a prospective standardised investigation procedure in a 
cohort of 124 referred patients over a 15 months period. All patients had laboratory 
confirmed giardiasis during the Bergen 2004 Giardia outbreak. Procedures included 
duodenal biopsies and aspirate, routine blood tests and faecal parasite and calprotectin 
investigations. Symptoms were recorded in 75 of the patients at the time of investigation, and 
in a control group of Giardia patients who rapidly recovered after metronidazole treatment. 
Chronic Giardia infection was found in 40 patients (32.3%). Duodenal biopsies showed signs 
of inflammation in 57 patients (47.1%), substantially higher in Giardia positive (87.2%) 
compared to Giardia negative patients (28.0%). The frequency of duodenal inflammation 
subsided over time. There were significant associations between persistent Giardia positivity, 
microscopic duodenal inflammation and a positive calprotectin test. Investigations could not 
determine an organic cause for the persistent symptoms. 
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Paper II:  Development of functional gastrointestinal disorders after Giardia 
lamblia infection. 
This study aimed to characterize the persistent abdominal symptoms 12-30 months after the 
onset of Giardia infection, and at least 6 months after Giardia eradication, according to the 
Rome II criteria and symptoms scores, as FGID development after infection with this non-
invasive protozoan had not previously been described. It was found that 66 (80.5%) of the 82 
patients included had symptoms consistent with irritable bowel syndrome (IBS) and 17 
(24.3%) patients had functional dyspepsia (FD). IBS was sub classified into D-IBS (47.0%), 
A-IBS (45.5%) and C-IBS (7.6%). Food and stress related symptoms in this group were 
similar to FGID patients in general. Patients were showing clinical symptoms consistent with 
Rome II FGID categories, and the IBS-subtype pattern was consistent with post-infectious 
IBS (PI-IBS). With no other specific cause for the symptoms it was concluded that acute 
Giardia infection may elicit functional gastrointestinal diseases. 
Paper III:  Human cellular immune response against Giardia lamblia five years 
after acute giardiasis. 
This was a proof of concept study to show that Giardia lamblia infection may induce a long-
term cellular mediated immunity and that this may be measured by a 3H-thymidine 
proliferation assay and flow cytometry analysis of activation markers HLA-DR, CD45RO, 
CD25 and CD26 in T-cell subsets. Peripheral blood mononuclear cells from 19 individuals 
with Giardia assemblage B infection five years previously and from 10 uninfected controls 
were cultured for 6 days with various antigen fractions obtained by sonicated Giardia
assemblage A and B trophozoites. The study shows that proliferation responses were 
variable, but significantly elevated in the group previously exposed to Giardia for nearly all 
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Giardia antigens tested. Responses to Giardia assemblage A and B correlated well, 
indicating that cellular immune responses are not assemblage specific. Activation marker 
responses were mainly seen in CD4 T-cells indicating the importance of this T-cell subset in 
the human immune response against Giardia. 
Paper IV:  Immunophenotyping and Giardia specific immunity in post-
giardiasis functional gastrointestinal disease and chronic fatigue syndrome.  
The aim of this study was to evaluate markers of immune dysfunction and specific anti-
Giardia CMI in post-infectious functional gastrointestinal disorders (PI-FGID) and chronic 
fatigue syndrome (PI-CFS) developing after Giardia infection. Five years after the outbreak 
48 patients reporting chronic fatigue in a questionnaire study three years after the outbreak 
and 22 Giardia exposed non-fatigued individuals and 10 healthy unexposed individuals were 
included and grouped according to Fukuda criteria for CFS (n=19) and idiopatic chronic 
fatigue (n=5) and Rome II criteria for FGIDs (n=54). 
No difference in Giardia specific CMI was found between Giardia exposed controls and PI-
FGID or PI-CFS patients. However, in peripheral blood, significantly increased levels of CD8 
T-cell in the PI-FGID group and significantly lower NK-cell levels in PI-CFS patients were 
found. NK-cell levels correlated well with both gastrointestinal and fatigue symptoms scores. 
A trend towards lower T-cell CD26 expression in PI-FGID and increased CD4 T-cell HLA-DR 
expression was seen. 
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5. RESULTS AND DISCUSSION 
5.1. Giardia infection - symptoms and duodenal inflammation 
Symptoms in the referred patients in Study I and II were recorded using the same ordinal 
scale and were most severe in the group with chronic Giardia infection and decreased over 
time in Study I. Symptoms scores, seen in the group as a whole, were largely stabilized in 
the patient population when measured again at the later time point when study II was 
performed. At all time points, bloating were the most severe symptom, only surpassed by 
diarrhea in ongoing giardiasis. Diarrhea figured as the second most severe symptom, closely 
followed by abdominal pain, in the Giardia negative patients at later time points. Similar to a 
small study of correlation between duodenal histology and diarrhea [41], we found abdominal 
pain and diarrhea to be associated with duodenal mucosal inflammation in study I. However, 
both these symptoms persisted even if inflammatory changes in routine biopsy findings 
normalized in the 11 repeated biopsies mentioned in Study II. 
Studies of assemblage and symptoms development have shown inconsistent results, 
reviewed in [40]. In three of these studies [196-198], it is the assemblage found to be less 
prevalent in each study population that is also found to be causing most symptoms. This was 
also the case in Bergen where assemblage A was found to be the most prevalent in sewage 
the year before the outbreak ref [199], and the outbreak Giardia strain was genotyped to be 
assemblage B [200]. An inverse relationship between community prevalence and the 
development of symptomatic infection for any given Giardia genotype is therefore an 
intriguing possibility. 
Differences in virulence in the outbreak strain cannot be excluded as a cause of variation in 
the clinical picture and duodenal inflammation, although there is little evidence for this. An 
indication for such differences is a recent study which found decreased post infection levels 
of the disaccaridases sucrase, maltase, and lactase in a mice model infected with the 
assemblage B strain, but not with the assemblage A strain [201]. Disaccaridase activities in 
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humans are well correlated with the level of duodenal inflammation [202]. The high degree of 
duodenal inflammation in adults presented in Study I was similar to another small study [41], 
but considerably higher than what has been reported in two large studies where genotype 
was not known [29, 203]. It is also plausible that the low percentage of duodenal 
inflammation in these two large studies was due because Giardia was a well-tolerated 
commensal in a part of the patients included, and that other pathology was leading to 
endoscopic examination. Another possible explanation is that the Bergen outbreak was 
caused by a more virulent assemblage B strain than seen in other studies. 
Hardly any intestinal inflammation was found in a study of children with giardiasis [42], 
suggesting a milder inflammatory reaction in lower age groups. In developing countries, the 
childhood Giardia prevalence is much higher than in adults [21] and the risk of going through 
several Giardia infections in childhood and develop a degree of immunity is high. Our study 
population resided in a non-endemic area and consisted mainly of adults. Possibly, a first 
infection with Giardia in adulthood more often results in symptomatic infection and stronger 
inflammatory reaction than a first Giardia infection in childhood. Such age dependent 
differences in disease presentation are well known for example in polio and hepatitis A viral 
infections [204, 205]. Another possible cause could be a higher infective dose in a 
waterborne outbreak, and symptomatic and inflammatory responses are reflecting 
differences in water intake habits. 
5.2 Abdominal symptoms and fatigue after giardiasis - 
consistent with PI-FGID and PI-CFS? 
No other pathogen was found in the many fecal samples taken before and during the 
outbreak. Although it cannot be totally excluded, there is therefore limited potential for a 
possible accompanying other factor to have a role in the persisting symptoms observed in 
our study population. After thorough clinical work-up and follow up of around 180 patients 
referred to the Department of Medicine at Haukeland University Hospital during the two first 
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years after the Giardia outbreak in 2004, we were not able to find a discernible organic 
diagnosis to explain their abdominal symptoms and fatigue (study I and II). Additionally we 
documented a pattern of IBS-subtypes with a high frequency of diarrhoeal symptoms and 
little constipation. This agrees well with previous descriptions of PI-IBS as a distinctive 
subgroup of IBS patients [91]. 
It is known from clinical experience that Giardia may cause prolonged symptoms for several 
weeks after successful treatment due to secondary lactose intolerance [12]. In Study II we 
found that many patients reported different kinds of food to worsen symptoms. Testing of 
duodenal lactase activity in 10 patients with PI-FGID at our hospital did not confirm lactase 
deficiency (unpublished data). Lactose-intolerance has also not been found to be a factor in 
the aetiology of PI-IBS after bacterial gastroenteritis in a previous study [206]. 
We therefore concluded that abdominal complaints in this post-giardiasis cohort were 
consistent with development of post-infectious functional gastrointestinal disorders and, in 
patients evaluated for fatigue at the department of neurology, also with CFS. 
The referred patients who reported persistent abdominal symptoms and fatigue were a 
subgroup of all individuals who had acute giardiasis during the outbreak. In a questionnaire 
study to all individuals with laboratory confirmed outbreak related giardiasis 2 years after the 
outbreak, the same pattern of abdominal symptoms was seen in 38% of the 1017 
respondents. Fatigue was reported in 41% of respondents [3]. Severe and protracted 
infection, measured as the number of treatment courses and delayed education, were 
associated with the development of abdominal symptoms and fatigue in the same population 
[207]. 
A follow up questionnaire study in the same population three years after the outbreak used 
validated Rome III criteria [74] and a validated fatigue scale [180] and also included a control 
group. This study found that 46.1% of previously Giardia infected patients suffered from IBS 
compared to 14.0% in unexposed controls, and that 62.6% of these also experienced chronic 
fatigue [208]. 
39
Five years after the outbreak all individuals in this exposed population, who reported chronic 
fatigue and who still lived in the vicinity of Bergen, as well as controls reporting no fatigue, 
were invited to participate in a new study. These individuals formed the study population of 
Study IV where we again found abdominal symptoms consistent with FGID and were able to 
also diagnose concurrent CFS, ICF and other medical causes that could plausibly explain the 
fatigue. In both the questionnaire studies and in the Study IV population, FGID and chronic 
fatigue were associated with each other. Only one of the 19 patients diagnosed with CFS in 
study IV did not have FGID. 
The development of PI-IBS after gastroenteritis is widely reported and acknowledged, and 
co-morbidity with depression and anxiety has been well investigated. The co-morbidity with 
CFS observed in our patient population has not been well-studied, with the two exceptions 
mentioned in the introduction [120, 144]. 
Moss-Morris et al found that the nature of the infection was a strong predictor of IBS, while 
premorbid levels of anxiety and depression better predicted CFS. The very prolonged FGID 
symptoms seen after Giardia-gastroenteritis in our patient population is consistent with this 
study. It would have been interesting to document the role of premorbid distress in the 
development of PI-FGID and PI-CFS in our population, but this would have been 
methodologically difficult to retrospectively. Although not a focus of the studies included in 
this dissertation we have experienced that many PI-CF/CFS patients recovered 2-4 years 
after the outbreak. It will be possible, in future studies, to look for differences in cytokine 
profiles of PI-FGID and PI-CFS as was done by Scully et al [120] by using stored plasma 
samples from the Study IV population. 
5.3 Cellular immunity as mechanism for PI-FGID and PI-CFS 
Some epidemiologic data support long term immunity against the non-invasive parasite 
Giardia [59, 61] and there are studies showing gradually increasing antibody titers with age in 
developing countries. Seroprevalence in a large Mexican study showed that 10% of one year 
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old infants, 40% of children < 10 years and 70% of adults > 25 years had IgG antibodies 
against G. lamblia in an ELISA assay with Giardia trophozoite soluble extract as antigen [50]. 
In addition to humoral immunity, a role for CMI could be assumed to be present, given the 
important role for CD4 T-cells to clear infection in mice [52, 53]. We were inspired by a 
human giardiasis case report showing a strong CMI measured 6 years later when stimulated 
with antigens from the infecting strain of Giardia in a 3H-thymidine assay [62]. We 
hypothesized that a stronger CMI might be a mechanism for development of PI-CFS and PI-
FGID which we investigated Study IV.  
First it was necessary to validate the assays used and to ascertain the presence of a Giardia
specific CMI 5 years after giardiasis. This was done by recruiting individuals who had 
laboratory confirmed giardiasis during the outbreak and a control group of people without 
prior known Giardia infection, and at low risk for having had it. Comparing the exposed no-
fatigue control group versus the presumed unexposed controls we found that assemblage A 
and B independent, significantly stronger responses in the group exposed to giardiasis five 
years previously (Study III). In the flow cytometric assay mainly CD4 cells were seen to 
become activated. This is consistent with the results obtained in mice and in the case report 
by Gottstein et al [52, 53, 62]. The triggering of responses both to assemblage A and B in 
this population who had gone through an assemblage B infection is indicating some shared 
antigens by both assemblages which could be possible candidates for vaccine development. 
In study IV, which was performed simultaneously with study III, we added data from 38 
patients who reported chronic fatigue 3 years after the outbreak. They were categorized 
according to clinical evaluation using the Fukuda criteria regarding CFS and ICF  [151] and 
according to responses to Rome II questionnaires regarding FGID. We evaluated the 
strength and quality of the CMI in these groups. While we still found a significant difference in 
CMI between all Giardia exposed participants and the Giardia unexposed, we did not find 
differences between the PI-CFS/ICF and PI-FGID patient groups and exposed controls. 
Evaluation of the specific CMI towards the infectious agent eliciting PI-FGID or PI-CFS has 
not been done before. Our result does not exclude an altered CMI against the culprit 
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pathogen, as even if equal to exposed healthy controls measured 5 years later it may still 
have caused a psyhconeuroendocrine dysfunction resulting in prolonged symptoms. In IBS a 
lower proliferative response in T-cells has been observed in IBS patients when PBMC were 
stimulated by anti-CD3 and anti-CD28 antibodies for 3 days [126]. Similar assays have 
largely shown similar or decreased proliferative responses in CFS, reviewed by Natelson et 
al [162]. We saw a weak decrease in the proliferative responses after stimulation with anti-
CD3 and anti-CD28 antibodies in the exposed patient groups, but this difference may have 
been larger if measured after 3 days in culture. It is therefore possible that a stronger specific 
CMI in the PI-FGID of PI-CFS groups is masked by unknown common factors also 
contributing to the symptomatology of CFS and IBS. 
5.4 Inflammation markers in PI-FGID and PI-CFS 
The large waterborne outbreak in Bergen led to a numerous people suffering from PI-CFS 
and PI-FGID. These conditions were described based on initial workup and follow up, and 
seeing some patients still reporting chronic fatigue led us to try to further clinically describe 
their illness and look for markers of underlying pathophysiology. Low grade inflammation has 
been put forward as having an important role in both CFS [156, 209] and FGID [84, 110], but 
may not be specific to these conditions [210]. A number of markers of immune activation in 
peripheral blood have been reported to differ between healthy subjects and patients with 
FGID or CFS.  We therefore evaluated some of these in our study population and found 
similar levels of almost all markers in our small study population. 
The reported elevated levels of CD26 in NK and T-cells [174] were not found in our PI-CFS 
group, rather a tendency for decreased levels in PI-FGID was found. HLA-DR expression on 
CD8 cells, which has been reported to be increased in three out of nine CFS-studies 
analyzing this marker [162], was not found. Instead a tendency towards increased HLA-DR 
expression on CD4 cells in the combined PI-CFS/ICF&FGID compared to the control group, 
a significant reduction in the small group recovered from fatigue compared to the PI-
42
CFS/ICF&FGID group. Regarding published FGID markers like 7 expressing CD4 or CD8 
T-cells [211], we found normal levels of this lymphocyte subset. 
In contrast to the decrease in NK-cells and increase in CD4 cells expressing HLA-DR in PI-
CFS, these markers were seen to be at normal levels in the groups who had recovered from 
chronic fatigue during the two years between the questionnaire and the clinical evaluation. 
NK-cell levels correlated significantly with fatigue scores. These data suggest that decreased 
NK-cells and elevated HLA-DR expressing CD4 T-cells are associated with ongoing fatigue 
in PI-CFS after Giardia infection. However, NK-cell levels also correlated well with abdominal 
symptoms scores which again correlated well with fatigue scores. There is therefore also a 
possibility that NK-cell levels are linked to the severity of the overall condition of the patients. 
While CD4 and CD8 T-cell numbers and percentages may fluctuate considerably within an 
individual over time, the CD4:CD8 ratio is found to be relatively stable [212]. CD4 and CD8 
T-cell subsets and ratio in FGID have been looked at in a few studies which did not find 
differences in T-cell subsets [121, 126]. However, two Chinese studies found lowered 
CD4/CD8 ratio in IBS patients; one due to high CD8 cell levels [128] and one due to low CD4 
cell levels [129]. 
The peripheral blood T-cell pattern with elevated CD8 levels resulting in a reduced CD4:CD8 
ratio is seen in patients suffering from a number of viral diseases like mononucleosis, 
dengue, RSV and cytomegalovirus infection and herpes simplex recrudescence as well as in 
chronic toxoplasmosis infection [212, 213]. In our patient population this pattern was related 
to PI-FGID and not to PI-CFS, even though the hypothesis of low grade viral 
infection/reactivation is a hypothesis of CFS morbidity [214]. In our population of PI-CFS we 
did find a lower level of NK-cells, which is another cell subset important for the elimination of 
virally infected/altered host cells, and it is possible that impaired NK cell function allows the 
persistence of chronic viral infection in CFS. 
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5.5 Conclusions and future perspectives 
PI-FGID has not been reported in the scientific literature before, but is recognized by 
clinicians. This may be because Giardia infection only occasionally cause the strong 
inflammatory response observed and documented in Study I. The development of PI-FGID 
and PI-CFS could be documented after the outbreak only because there were a large 
number of people simultaneously being infected and a substantial proportion were 
developing the conditions described in these studies. 
In summary, there were no other pathogen found during the outbreak, and a strong and 
prolonged intestinal inflammatory reaction has been documented in many of the patients with 
persistent or chronic inflammation (Study I). No discernable cause for symptoms were found 
(Study II) and symptoms were consistent with Giardia induced post-infectious FGID and PI-
CFS that for some patients were still present five years after the outbreak. The outbreak 
infection caused a long term cellular immunity that was not a predictor of development of the 
post-infectious sequels observed. In patients 5 years after the outbreak we found signs of 
immune dysfunction with low NK-cell levels in PI-CFS and elevated levels of CD8 in PI-FGID. 
It is not clear whether these findings are cause or effect of these disorders. 
At this time, 7 years after the outbreak it is heartening to see many of the referred patients 
who developed severe FGID and debilitating CSF have recovered or improved considerably. 
We sincerely hope the research that has taken place alongside the clinical work-up and 
follow-up of the patients will be benefitting them and future patients with these disorders. 
Future research in collected materials and follow up studies will hopefully provide more 
knowledge on mechanisms and potential treatment options. 
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Summary Objectives: After a large waterborne outbreak of Giardia infection in Bergen,
some patients experienced persisting abdominal symptoms despite metronidazole treatment.
This study aimed at investigating possible causes for their symptoms.
Methods: Over a 15 months period, 124 referred patients were evaluated in a prospective cohort
analysiswitha standardised investigation includingduodenalbiopsies andaspirate,blood tests and
faecal parasite and calprotectin tests. Recovered subjects were recruited for symptom analysis.
Results: Persisting Giardia duodenalis infection was found in 40 patients (32.3%). Duodenal biop-
sies showed signs of inflammation in 57 patients (47.1%). Microscopic duodenal inflammation was
present in 34 (87.2%) of theGiardia positive and 23 (28.0%) of theGiardia negative patients. There
were significant associations between persistent Giardia positivity, microscopic duodenal inflam-
mationandapositivecalprotectin test. Duodenalaspirateandduodenalbiopsiesperformedpoorly
in diagnosis of persistent giardiasis.
Conclusions: In patients with persisting symptoms after metronidazole treated Giardia infection
we commonly found chronicGiardia infection andmicroscopic duodenal inflammation, especially
in illness duration less than 7 months. Both these findings subsided over time. Increasingly, inves-
tigations could not determine a definite cause for the persistent symptoms. The very long-term
post-giardiasis diarrhoea, bloating, nausea and abdominal pain documented here need further
study.
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Introduction
Giardia duodenalis is a major cause of waterborne out-
breaks of gastroenteritis.1 The clinical picture varies from
asymptomatic infection in more than half of infected cases
to severe illness and hospitalisation.2e4 Common symptoms
include diarrhoea, flatulence, excessive fatigue, nausea,
foul smelling stools, abdominal cramps and weight loss.
Giardia infection is normally a self-limiting disease with
symptoms spontaneously resolving and stool samples be-
coming negative after around 3 weeks.5 Symptoms may
last for several weeks even after clearance of the parasite,
due to acquired lactose intolerance which may occur in 20e
40% of cases.6 One study has shown that 16% of infected
individuals became chronically infected.5 These patients
experience variable symptoms of loose stools, weight loss,
abdominal pain, malabsorbtion and malaise. Symptoms of
chronic giardiasis are often indistinguishable from irritable
bowel syndrome.7
In autumn 2004, after a period of heavy rainfall, an
outbreak of giardiasis due to contaminated drinking water
occurred in the inner city of Bergen, a coastal city in
Western Norway. Around 2500 cases were treated with
metronidazole.8 The outbreak subsided with few new cases
after November 2004. A total of 1300 laboratory confirmed
cases were reported. The outbreak strain was genotyped to
be assemblage B.9,10
In some patients symptoms persisted even after several
treatment courses with metronidazole. They were referred
from general practitioners for specialist evaluation. The
magnitude of the outbreak offered a unique opportunity to
increase our knowledge about Giardia infection and its
manifestations in a developed country setting. The objec-
tive of the present study was to investigate possible causes
for the persisting symptoms in this group of patients.
Patients and methods
Study patients
From January 2005 to March 2006 altogether 139 patients
were referred to Haukeland University Hospital and exam-
ined according to a standardised procedure at the out-
patient department. These patients had:
1. Clinically suspected giardiasis with onset of symptoms
(including two or more of the following five symptoms;
loose stools, nausea, weight loss, fatigue, foul smelling
faeces) from June 2004 until February 2005.
2. Confirmed laboratory diagnosis of giardiasis at least
once during the initial illness.
3. Persisting abdominal symptoms after one or more treat-
ment courses of metronidazole.
Twelve of the referred patients did not fulfil these
criteria and were excluded from the present evaluation.
One patient had never received metronidazole and 11 did
not have laboratory confirmed giardiasis. Investigations
concluded with inflammatory bowel disease in two patients
and one patient had considerable comorbidity and could not
complete the investigations. The remaining 124 patients
were included in this analysis. They had received from one
up to four (mean 2.0) courses of metronidazole before
referral. Metronidazole is the only licensed drug for giardi-
asis in Norway.
Study design
This was a prospective cohort study with standardised
investigations of patients with persisting symptoms follow-
ing Giardia infection. Only findings and symptoms at the ini-
tial visit are included in this report. All examinations and
investigations were performed as part of the clinical evalu-
ation. For analysis of symptom scores, a control group of 19
individuals were recruited. All of them had had laboratory
confirmed giardiasis during the outbreak, and they rapidly
recovered after metronidazole treatment and they had
three microscopy negative faecal samples at the time of
symptom recording 12e18 months after their Giardia infec-
tion. The Regional ethics committee approved the data
collection and analysis of the study.
Symptoms recording
The severity of abdominal symptoms was determined by an
irritable bowel syndrome symptom questionnaire11 includ-
ing nausea, bloating, abdominal pain, diarrhoea, constipa-
tion and anorexia. Patients and controls graded these
symptoms on an ordinal scale from 0 to 10 with 0 Z no
symptoms and 10 Z severe symptoms.
Blood samples
Levels of haemoglobin, mean corpuscular volume, ESR,
s-calcium, s-B12, s-ferritin, s-iron, s-zinc, thyroidea stimu-
lating hormone, parathyroid hormone, immunoglobulins A,
G and M, serum anti-endomysial and anti-tissue trans-
glutaminase antibodies were measured.
Upper endoscopy
Upper endoscopy was performed in 121 patients. Biopsies
were taken from the distal part of duodenum and were
evaluated by an experienced pathologist blinded to other
clinical information about the patients. Biopsy results were
divided into three groups: normal histology (grade 0), mild
pathology (grade 1) andmoderate to severe pathology (grade
2). Grade 1 biopsies showed inflammation with oedema and
infiltration of leukocytes and increased number of plasma
cells in the lamina propria. Grade 2 biopsies showed in
addition to the inflammatory changes of grade 1, architec-
tural distortionwith shorteningandbluntingof intestinal villi.
Duodenal content was collected after instillation of 5 ml
0.9% NaCl, and examined by microscopy for Giardia tropho-
zoites after centrifugation. This was discontinued after
being performed in 65 patients, as all samples until then
had been negative.
Faecal samples
Three faecal samples from three different defecations,
normally collected over a period of 2e3 days, were
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analysed by microscopy and one sample for culture of bac-
terial pathogens. Conventional formalin-ether concentra-
tion technique was used before microscopy. A faecal
antigen test (ImmunoCardSTAT! Cryptosporidium/Giardia
rapid assay; Meridian Bioscience) was performed in the
first 109 patients, but was then discontinued due to poor
performance compared with microscopy (unpublished ob-
servations). Calprotectin, a marker of intestinal inflamma-
tion,12 was analysed by the ELISA-based fhiCal Test
(NovaTec Immundiagnostica GmbH, Germany) from one
faecal sample per patient.
Statistical methods
Over time, substantial changes in the analysed parameters
were observed. Data were therefore grouped after illness
duration into three-month periods for analysis. Illness dura-
tion was defined as the time from onset of symptoms until
investigations in this study were performed. Cases referred
during the last periods were combined in some analyses, as
there were few patients referred in these periods.
Fisher’s exact test was used for testing independence
between histology, calprotectin and Giardia result. Wil-
coxon-ManneWhitney’s test was used for comparing blood
and calprotectin tests, and for analysis of variance for the
level of symptoms. Linear regression analysis was used to
investigate the potential influence of Giardia results on
the symptoms adjusted for biopsy result. Values are given
as mean with standard error unless otherwise stated. Level
of significance was set at p < 0.05. SPSS 14 was used for all
statistical analyses.
Results
There were 48 men (38.7%) and 76 women (61.3%), mean
age 31, ranging from 16 to 79 years (Table 1), similar to the
age distribution of the patient population of the epidemic.8
No previous abdominal complaints were stated by 85% of
the patients, the rest reporting various kinds of mild to
moderate abdominal symptoms, evenly distributed within
age groups. In the control group there were 10 men
(52.6%) and 9 women (47.4%), mean age 32, ranging from
23 to 46 years old. The population was generally healthy
young adults with little co-morbidity.
Faecal samples
Giardia cysts were found by microscopy of faecal samples
in 37 patients and faecal antigen test identified 3 additional
patients as Giardia positive. Thus, chronic Giardia infection
was found in 40 of 124 patients (32.3%). In the remaining
patients both microscopy and antigen tests were negative.
37.5% of the male patients were Giardia positive compared
to 28.9% of the female patients, the difference not being
statistically significant. There were no significant differ-
ences between age groups. Almost all patients found to
be Giardia positive (32 out of 40) presented with an illness
duration of less than 7 months. The number of Giardia
positive patients, and patients with pathological duodenal
biopsies decreased with increasing illness duration
(Fig. 1). Microscopy of duodenal aspirate was negative in
all 65 samples where this analysis was performed, including
25 patients with Giardia positive faecal samples. The
patient samples tested for Cryptosporidium were all nega-
tive, either with the antigen-test alone, or by control Ziehl-
Nilsen staining of samples in cases of weakly positive
antigen test.
Faecal calprotectin levels were elevated in 26 (23.6%) of
the patients. Seventeen out of 39 Giardia positive cases
(43.6%) had pathological levels compared to 9 out of 71
Giardia negative cases (12.7%). Positive calprotectin tests
were associated with pathological biopsy (p Z 0.003) and
chronic Giardia infection (p < 0.001) (Fisher’s exact test)
Table 1 Study population characteristics
Giardia status Alla
Giardia positivea Giardia negativea
Females, n 22 (55.0%) 54 (64.3%) 76 (61.3%)
Age 16e25 years, n 15 (37.5%) 35 (41.7%) 50 (40.3%)
Age 25e35 years, n 16 (40.0%) 25 (29.8%) 41 (33.1%)
Age 35e79 years, n 9 (22.5%) 24 (28.6%) 33 (26.6%)
Previous minor abdominal symptoms, n 7 (20.0%) 9 (12.5%) 16 (15.0%)
Disease duration (days), mean  SE* 197  16 261  14 240  11
Total symptoms score, mean  SE 27.9  2.2 23.3  1.3 24.6  1.1
Calprotectin positive (>50 mg/kg), n* 17 (43.6%) 9 (12.7%) 26 (23.6%)
F-calprotectin mg/kg, median (75%ile)b,* 28 (119.0) <20 (<20) <20 (44.8)
Haemoglobin g/dL, mean  SE 14.5  0.2 14.1  0.1 14.2  0.1
s-ferritin mg/L, mean  SE 60.8  6.0 76.2  7.6 71.3  5.6
s-B12 pmol/L, mean  SE* 281.8  24 334.3  15 316.8  13
s-zinc mmol/L, mean  SE 11.7  0.3 12.5  0.2 12.2  0.1
ESR mm/h, mean  SE 10.0  1.6 10.0  1.4 10.0  1.1
*Significant differences between Giardia positive and Giardia negative with p-value <0.05.
a All percentages given as percentage of Giardia positive or Giardia negative or all.
b Results outside of the quantitative range were set to 10 when <20 mg/kg and to 1275 when >1275 mg/kg.
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and were evenly distributed among sex and age groups.
Faecal samples from all patients were negative for growth
of bacterial pathogens.
Upper endoscopy and histology
Only occasionally were there macroscopic signs of duode-
nitis (Table 2). It was found more often in Giardia positive
patients than in Giardia negative patients, but the differ-
ence was not significant. Microscopic duodenal inflamma-
tion was found in 72.4% of patients with illness duration
of 2e4 months. In the whole cohort, 57 patients (47.1%)
had either grade 1 or grade 2 pathological duodenal biop-
sies. A higher percentage of men (52.2%) compared to
women (44.0%) had pathological duodenal biopsies, al-
though not statistically significant. Throughout the study
period, duodenal inflammation was more frequently found
than Giardia positivity. With increasing illness duration an
increasing fraction of patients had normal duodenal biop-
sies (Fig. 1). We found a significant association between
Giardia positivity and pathological histology (grade 1 and
2 combined), the strongest association occurring early after
the acute infection (Table 3). Giardia trophozoites were
visible in duodenal biopsies in only 4 (10%) of the 40 cases
with Giardia positive faecal samples.
Blood tests
One patient had IgA deficiency with non-measurable IgA
levels and had visible Giardia trophozoites and grade 2
duodenal inflammation in the duodenal biopsy. In nine
other patients the levels of IgA were below the normal
range (1.00e4.10 g/L) with values in the range 0.57e0.86.
Only one of these was Giardia positive and three had grade
2 pathological biopsies.
B12 levels were significantly lower (p Z 0.008) in the
Giardia positive group (mean: 281.8  24 pmol/L) than in
the Giardia negative group (mean: 334.3  15 pmol/L).
The normal range is 175e700 pmol/L. There was no correla-
tion between B12 levels and duodenal inflammation. Other
blood tests were generally within normal ranges, and
showed neither significant differences over time nor any
correlation with Giardia presence or with histological
findings (Table 1).
Eight patients in this study had elevated anti-tissue
transglutaminase antibodies (relative OD 22.3e441.7, me-
dian 29.9). Five of these patients were also positive for
anti-endomysial antibodies and had pathological duodenal
biopsies. Four of these were also Giardia positive at the
time of investigation.
Symptoms
The symptom questionnaire was answered by 75 (60.5%) of
patients at the time of investigation. Bloating was reported
to be the most severe symptom (mean 6.2  0.36), fol-
lowed by diarrhoea (mean 5.6  0.36), abdominal pain
(mean 5.2  0.31) and nausea (mean 4.1  0.36). Constipa-
tion (mean 1.8  0.29) and anorexia (mean 1.7  0.25)
were less often reported.
Total symptoms scores changed over time with the
highest scores in the periods 2e4 months (mean 27.9 
3.2) and 5e7 months (28.0  1.4). Patients with illness du-
ration 8e10 months reported a lower total symptom score
of 22.2  2.9. For illness duration of 11e18 months, a total
score of 17.3  1.7 was reported. This was still significantly
higher (p Z 0.002) than the total symptom score in the
control group which was 7.1  2.2. Individual symptom
scores among patients were significantly higher than symp-
tom scores in the control group for all symptoms except for
constipation (Table 4).
We analysed symptom scores from patients with illness
duration 2e7 months separately, to avoid the influence of
the overall decrease in symptom scores. The patients
with microscopic duodenal inflammation (grade 1 and 2
combined), reported more abdominal pain (p Z 0.046)
and more diarrhoea (pZ 0.05) than patients with normal
histology. With regard to Giardia result or calprotectin re-
sult we found no significant differences in symptom scores.
Figure 1 Percentage of patients with Giardia positive stool
samples and microscopic duodenal inflammation by illness
duration.
Table 2 Histology related to Giardia status






Normal Grade 1 Grade 2 Normal Grade 1 Grade 2
No of patients 6 5 13 21 5 59 9 14
Percentc 15.4% 12.8% 33.3% 53.8% 6.1% 72.0% 11.0% 17.1%
a N Z 39 as upper endoscopy not performed in one of these patients.
b N Z 82 as upper endoscopy was not performed in two of these patients.
c Percent of Giardia positive or Giardia negative patients where upper endoscopy was performed.
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In patients with illness duration 8e18 months, abdominal
pain was reported to be significantly more severe in Giardia
positive patients. No significant differences were found
with regard to nausea, bloating, constipation and anorexia.
Discussion
Reports on pathology in duodenal biopsies in giardiasis
patients vary greatly. Different virulence of Giardia strains,
host factors or differences in infection duration and sever-
ity may explain these variable results. Our patient popula-
tion was a selection of cases with persisting symptoms,
which were severe enough for the patient to be referred
for specialist evaluation. Duodenal inflammation was found
in 87.2% of Giardia positive and 28% of Giardia negative
patients. The relatively high number of patients with ab-
normal duodenal histology in our study is consistent with
some earlier reports of the prevalence of mucosal pathol-
ogy with 13 out of 17 patients having some degree of villous
shortening or inflammation.13 However, it is much higher
than results from a large Austrian study of 462 patients
with Giardia parasites above the duodenal mucosa, where
only 3.7% had microscopic duodenitis.14 Elevated levels of
calprotectin correlated well with findings of histological
duodenal inflammation and chronic Giardia infection, sup-
porting our findings of an increased inflammatory reaction
due to giardiasis in these patients.
The outbreak strain was genotyped to be assemblage B.
We are not aware of any studies of relations between
genotype and duodenal inflammation, but it is an interest-
ing possibility that assemblage B may cause a higher degree
of duodenal inflammation in adults than what has been
reported in previous studies where genotype was not
known.
The patients in our study were adults with symptoms of
bloating, diarrhoea, abdominal pain and nausea, and they
had ongoing or recent assemblage B infection. There are
a few studies relating Giardia genotype to symptoms. A
study of 18 Dutch patients between 8 and 60 years of age
reported patients with assemblage B infection to have
a more acute and severe symptomatology with persistent
diarrhoea, than patients with assemblage A who had
milder, intermittent diarrhoea.15 A study in children under
5 years of age in Western Australia found assemblage A to
be correlated with diarrhoea, while the more common as-
semblage B was often asymptomatic.16 Also a study from
Bangladesh showed that assemblage B infection was often
asymptomatic, but it was associated with a higher parasite
load. Infection with the less common assemblage A
Table 3 Histological findings among Giardia positive and Giardia negative cases by illness duration
Illness duration Duodenal biopsy pathological Duodenal biopsy normal p-value* Fisher’s
exact testGiardia positive Giardia negative Giardia positive Giardia negative
2e4 months 15 6 0 8 0.001
5e7 months 14 12 2 17 0.004
8e18 months 5 5 3 34 0.007
*p-value for association between Giardia positivity and pathological duodenal biopsy.
Table 4 Symptom scores of patients by Giardia result and symptom scores from recovered controls
Illness duration Symptoma Patients Recovered controls
Giardia positive Giardia negative
2e7 months NZ 17 N Z 28
Nausea 5.1  0.7 5.0  0.6 na
Bloating 6.8  0.8 6.5  2.9 na
Abd. pain 6.1  0.6 5.5  0.6 na
Constipation 1.8  0.6 2.3  0.5 na
Diarrhoea 7.6  0.5 5.9  0.6 na
Anorexia 1.5  04 2.4  0.5 na
8e18 months NZ 4 N Z 27 N Z 19
Nausea 6.3  2.2 2.4  0.5 0.8  0.4c
Bloating 5.8  2.1 5.5  0.6 2.3  0.6c
Abd. pain 7.0  1.1b 4.0  0.5 1.4  0.4c
Constipation 0.3  0.3 1.5  0.5 1.5  0.3
Diarrhoea 4.3  2.1 4.1  0.5 1.2  0.5c
Anorexia 1.5  0.9 1.1  0.4 0.1  0.1c
a Symptom scores given as mean  SE of the mean.
b Abdominal pain was reported significantly more often (pZ 0.026) among Giardia positive vs Giardia negative patients with illness
duration 8e18 months, although caution should be taken as there were only 4 patients in the Giardia positive group.
c Values for patient symptom scores in both periods were significantly higher than control symptom scores except for constipation.
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genotype was more often associated with diarrhoea. How-
ever, in a recent study from Ethiopia, assemblage B was
found to give symptomatic infection more often than the
commoner assemblage A.17 Interestingly, two of these as-
semblage B subtypes were also found during the Bergen
outbreak. Also in Norway assemblage A is the genotype
most commonly found.18
In three of the studies mentioned, it is the assemblage
found to be less prevalent in each community that is also
found to be causing most symptoms. An inverse relationship
between community prevalence and the development of
symptomatic infection for any given Giardia genotype is an
intriguing possibility.
Our study population consisted of relatively young
adults, with an age distribution similar to that reported
from the epidemic. One possible explanation for the
frequency of persisting symptoms and duodenal inflamma-
tion could be that many of our patients most likely have
never been exposed to Giardia duodenalis, or its assem-
blage B subtype before. The Giardia infection may there-
fore have elicited a different immune response in these
persons compared to those who have been exposed to this
antigen in childhood. Another possible cause could be
a higher infective dose in this age group, due to differences
in water intake habits.
The finding of inflammation in the duodenal mucosa of
some Giardia negative patients might be caused by the in-
testinal mucosa recovering slowly after the infection has
been cleared. Severity and duration of mucosal inflamma-
tion may be a risk factor for development of long term
symptoms. This would be in line with recent research link-
ing prolonged intestinal inflammation to the development
of post-infectious functional bowel disorders.19
B12 deficiency has been described in giardiasis.20,21 This
agrees with our findings of lower B12 levels among the
Giardia positive patients. IgA deficiency is a risk factor
for persistent Giardia infection in mice22 and this is consis-
tent with one patient in our study who had non-measurable
IgA and persistent infection. We did not find any plausible
host related explanation for the lack of response to metro-
nidazole treatment in the other cases of chronic Giardia in-
fection. None of the patients had known HIV-infection or
used immunosuppressive drugs. Less severe IgA deficiency
seems from our results not to be associated with persistent
infection, and further studies are needed to determine if it
may be associated with persistent symptoms. The elevated
levels of tissue transglutaminase antibodies in eight pa-
tients are interesting and further follow up may reveal if
Giardia infection can play a role in the onset of coeliac
disease.
Duodenal aspirate microscopy showed no positive re-
sults. Another study has also found duodenal aspirate to be
of doubtful value in diagnosis of giardiasis compared to
faecal samples with a sensitivity of 20.5% for wet mount of
duodenal fluid.23 The method of NaCl-instillation and then
suction of fluid rather than direct suction may be an expla-
nation for the poor outcome of this test in our study.
The findings of negative duodenal aspirates and very few
Giardia positive cases showing visible trophozoites in duo-
denal biopsies suggest a low parasite burden in the duode-
num in our patient population, which may be due to long
standing or subsiding infection and previous treatment
attempts. This is supported by a study investigating pa-
tients with long lasting abdominal symptoms where duode-
nal biopsies were not a very sensitive marker of giardiasis.24
Out of nine stool microscopy positive patients only two
patients had visible Giardia trophozoites upon histological
examination.
Increased severity of diarrhoea correlating with increas-
ing duodenal mucosal pathology in giardiasis has been
shown previously.13 This is consistent with our results,
and we also find a correlation to abdominal pain. An Italian
study25 showed that acute giardiasis may worsen symptoms
in patients with a previous diagnosis of irritable bowel
syndrome. However, in our study population only 15.0%
reported mild to moderate previous bowel complaints.
This is only slightly more than the background prevalence
of irritable bowel syndrome of around 10% in our patients’
age group in Norway.26
Microscopy of three stool samples for Giardia cysts has
a sensitivity of 85e90%.27,28 The faecal-antigen test did
not improve the diagnostic yield (data not shown). In the
present study 85% of patients with illness duration of
11 months or more were found to be Giardia negative.
Most of them had been tested repeatedly with Giardia neg-
ative faecal samples in the time before referral. We are
therefore convinced that these patients are truly no longer
harbouring Giardia parasites. Symptoms have been reported
to resolve in 60e70% of patients with chronic giardiasis when
the parasites have been successfully eradicated.29,30 Persis-
tent abdominal symptoms in travellers, where Giardia may
be an etiological agent, has been described,31 but to our
knowledge no long term follow-up or description of post-
treatment symptomatic Giardia negative cases has been
published.
We studied 124 patients presenting over a period of 11⁄4
year with persistent abdominal symptoms after a Giardia
outbreak. In the first months of this study many patients
were found to have persisting Giardia infection and even
more patients had duodenal microscopic inflammation.
These findings subsided over time and patients increasingly
presented without detectable Giardia parasites.
With the investigations performed in this study, we have
not been able to positively identify the cause of the very
prolonged abdominal symptoms in the Giardia negative
patients. Prolonged lactose intolerance, an undiagnosed
pathogen, bacterial overgrowth, a change in mucosal archi-
tecture, or development of a post-infectious functional
bowel disorder are possible explanations that should be
considered. Studies to further explore this phenomenon
are needed.
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Abstract
Background: Functional gastrointestinal disorders (FGID) may occur following acute
gastroenteritis. This long-term complication has previously not been described after infection with
the non-invasive protozoan Giardia lamblia. This study aims to characterize persistent abdominal
symptoms elicited by Giardia infection according to Rome II criteria and symptoms scores.
Methods: Structured interview and questionnaires 12–30 months after the onset of Giardia
infection, and at least 6 months after Giardia eradication, among 82 patients with persisting
abdominal symptoms elicited by the Giardia infection. All had been evaluated to exclude other
causes.
Results: We found that 66 (80.5%) of the 82 patients had symptoms consistent with irritable
bowel syndrome (IBS) and 17 (24.3%) patients had functional dyspepsia (FD) according to Rome II
criteria. IBS was sub classified into D-IBS (47.0%), A-IBS (45.5%) and C-IBS (7.6%). Bloating,
diarrhoea and abdominal pain were reported to be most severe. Symptoms exacerbation related
to specific foods were reported by 45 (57.7%) patients and to physical or mental stress by 34
(44.7%) patients.
Conclusion: In the presence of an IBS-subtype pattern consistent with post-infectious IBS (PI-IBS),
and in the absence of any other plausible causes, we conclude that acute Giardia infection may elicit
functional gastrointestinal diseases with food and stress related symptoms similar to FGID patients
in general.
Background
Long term abdominal symptoms may develop after acute
gastroenteritis and was first described in 1962 [1]. These
symptoms are clinically similar to functional gastrointes-
tinal diseases (FGID) and may be classified using the
Rome II criteria for such illnesses. Symptoms often fulfil
the criteria for irritable bowel syndrome (IBS) and the
term post-infectious irritable bowel syndrome (PI-IBS) is
often used for this condition [2]. It has been shown to
occur following viral, bacterial and amoebic gastroenteri-
tis and after trichinellosis [1,3,4]. A meta-analysis found
the odds of developing irritable bowel syndrome (IBS) to
be increased sixfold after acute gastroenteritis [5]. Previ-
ously, Giardia infection has been found to trigger abdom-
inal symptoms in patients with established IBS[6], and
Giardia should be ruled out as a possible cause in patients
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with IBS-like symptoms[7]. However, post-infectious
functional gastrointestinal diseases elicited by infection
with the non-invasive protozoan Giardia lamblia have not
been described before. Similarly, the relation of patients'
abdominal symptoms and food types and the influence of
physical or mental stress have been well researched
among IBS-patients in general[8,9], but little data exists
regarding such relations in post-infectious FGIDs.
Giardia lamblia is a parasite of the small intestine occur-
ring endemically, or as the cause of waterborne outbreaks.
The parasite is commonly found in children in developing
countries and in travellers to endemic regions. It causes
infections varying from asymptomatic to protracted and
severe illness with diarrhoea, weight loss and malabsorb-
tion[10]. After an outbreak in autumn 2004 of assemblage
B giardiasis in Bergen, Norway, many patients experienced
long-lasting abdominal symptoms despite one or several
courses of metronidazole. They were referred to the local
university hospital for evaluation. Extensive work-up
revealed a surprisingly high rate of duodenal inflamma-
tion both in patients with and without evidence of
chronic infection [11]. All Giardia positive patients were
treated successfully[12]. However, symptoms remained in
many patients despite eradication of the parasite, and they
were followed up regularly.
The main aim of this study was to evaluate the abdominal
symptoms according to the Rome II criteria for FGID
among patients with persisting abdominal symptoms 12–
30 months after the onset of Giardia infection, and more
than 6 months after Giardia eradication. Secondarily, we
included some questions about the symptoms relation to
food types and stress.
Methods
This is a prospective study describing the results of ques-
tionnaires and structured interviews during follow-up vis-
its of patients with persisting symptoms following Giardia
infection. The data were collected during a 16 month
period from January 2006 until April 2007.
All 82 patients included in this study had laboratory con-
firmed giardiasis during an outbreak in 2004. They had
been successfully treated and were confirmed Giardia neg-
ative by microscopy of three or more faecal samples at
least 6 months prior to inclusion in this study. An exten-
sive work-up including upper endoscopy with duodenal
biopsies, routine blood screening tests, immunoglobu-
lins, IgE, serum anti-endomysial, anti-tissue transglutam-
inase antibodies and faecal calprotectin had not produced
any findings to explain their symptoms [11]. In 11
patients included in this study, repeated routine duodenal
biopsies were taken approximately one year after the ini-
tial work-up, and these were reviewed with regard to
inflammatory changes.
After the initial extensive work-up, patients came for fol-
low up visits where, in addition to routine clinical exami-
nation, a structured interview was performed with regard
to previous abdominal symptoms, and symptom exacer-
bation related to food types or physical or mental stress.
In the interview most patients denied previous abdominal
illness, while 14 (17.1%) had experienced some previous
abdominal symptoms. All these 14 patients reported con-
siderable more abdominal problems after Giardia infec-
tion than they had had before. Only 5 of them reported
previous contact with a physician about their abdominal
problems. For clarity we chose to give results for patients
without previous abdominal complaints separately in the
analysis.
Patients also filled in a questionnaire regarding their cur-
rent abdominal symptoms allowing evaluation of IBS
according to the Rome II criteria[13]. As it became evident
that functional dyspepsia (FD) was occurring in our
patient population, Rome II FD criteria questions were
included in the questionnaires. IBS patients were sub clas-
sified into diarrhoea-predominant IBS (D-IBS: two or
more diarrhoea symptoms and a maximum of one symp-
tom of constipation), constipation-predominant IBS (C-
IBS: two or more constipation symptoms and a maximum
of one symptom of diarrhoea) and alternating IBS (A-IBS:
all subjects with IBS not qualifying for D-IBS or C-IBS).
Symptom severity, for the last month, of nausea, bloating,
abdominal pain, diarrhoea, constipation and anorexia
was quantified by patients grading these symptoms on an
ordinal scale from 0 – 10 with 0 = no symptoms and 10 =
severe symptoms.
Statistical analysis was performed using SPSS 16.0. The
Regional ethics committee and the Norwegian Social Sci-
ence Data Services approved the data collection and anal-
ysis of the data.
Results
There were 52 females (63.4%) and the mean age was
31.8 years (range 18–61). Analysis of the collected data
showed a high frequency of patient's symptoms fulfilling
the Rome II IBS criteria with D-IBS and A-IBS of similar
prevalence (Table 1). IBS-C was uncommon. Regarding
FD, 17 cases were identified and 10 of these also had con-
current IBS. The 6 cases fulfilling neither FD nor IBS crite-
ria could be put into one or more of the Rome II
categories; functional abdominal pain, functional diar-
rhoea and functional bloating.
No significant sex differences were found regarding IBS
subtypes, symptom scores, influence of stress or subjective
food intolerance, only trends towards more FD among
females (p = 0.09) and more females reporting previous
abdominal symptoms (p = 0.07). Patients with FD had
similar symptom scores as non-FD patients except for the
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constipation score which was 2.85 in FD patients and 0.65
in non-FD patients with a p-value < 0.001.
Bloating was the symptom reported to be most severe
(Table 2). In fact only two patients reported nil bloating.
Symptoms of diarrhoea and constipation varied consist-
ently with IBS subtype. No gender differences were found,
only a trend towards nausea being more severe among
females (p = 0.08).
The question of food related worsening of symptoms was
answered by 78 patients. The majority of patients (57.7%)
reported their post-giardiasis abdominal problems to
worsen after intake of certain food items. They were asked
to name the food items they had begun to avoid. Milk and
milk products were mentioned spontaneously by 27% of
the patients. Other common food items mentioned were
alcohol containing beverages (18.4%), wheat flour prod-
ucts (14.5%) and coffee (6%).
In 76 patients who responded to the question about the
influence of physical or mental stress on their abdominal
symptoms, 44.7% felt that their abdominal illness was
worsened by stress. No correlations were found between
IBS-subtypes and symptoms exacerbation related to stress
and food types.
Signs of inflammation with infiltration of inflammatory
cells, with or without shortening and blunting of intesti-
nal villi, were found in 8 out of 11 of these patients during
the first workup in spring 2005. One year later, repeated
routine duodenal biopsies were normal in ten and
improved in one of these patients, although all these
patients still had troubling abdominal symptoms (data
not shown).
Discussion
Clinical characteristics of a relatively large number of
patients seeking help for long lasting abdominal symp-
toms after Giardia infection are described in this study. An
extensive follow-up of these patients over three years has
not revealed any specific illness, which can explain the
symptoms seen in our study population. The prolonged
symptoms in parasitologically successfully treated
patients came as a surprise, as such complications have
not been described after Giardia infection before.
Table 1: Frequency of FGID and relation of abdominal symptoms to food types and stress




N % N %
IBS all subtypes 54 79.4 66 80.5
D – IBS1 25 46.3 31 47.0
A – IBS1 27 50.0 30 45.5
C – IBS1 3 5.6 5 7.6
FD2 14 21.9 17 24.3
IBS & FD2 8 12.5 10 14.3
Other FGID (not IBS/FD) 6 8.8 6 7.3
Food related symptoms3 37 56.1 45 57.7
Stress related symptoms4 26 40.6 34 44.7
1 Percentages within subgroup with IBS
2 70 patients with available FD data
3 78 patients with available food related data
4 76 patients with available stress related data











Nausea 2.8 ± 0.4 3.1 ± 0.5 3.4 ± 1.5 3.0 ± 0.8 3.0 ± 0.3
Bloating 6.2 ± 0.4 7.0 ± 0.4 8.0 ± 0.8 5.4 ± 0.8 6.4 ± 0.2
Abd.pain 3.9 ± 0.5 4.6 ± 0.4 5.2 ± 1.0 3.8 ± 0.6 4.2 ± 0.3
Constipation 1.7 ± 0.5 3.1 ± 0.5 3.8 ± 1.2 0.9 ± 0.3 2.2 ± 0.3
Diarrhea 5.4 ± 0.4 4.5 ± 0.5 3.4 ± 1.0 4.3 ± 0.7 4.8 ± 0.3
Anorexia 2.0 ± 0.5 1.5 ± 0.4 2.4 ± 0.8 1.1 ± 0.5 1.7 ± 0.3
Total score 22.1 ± 1.5 23.9 ± 1.6 26.2 ± 5.0 19.1 ± 2.1 22.3 ± 1.0
Values given are mean scores ± standard error.
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There have been several Giardia outbreaks described,
among others in Solna, Sweden[14], Creston, Canada
[15] and Aspen highlands, USA[16]. However, no follow-
up studies have looked at persistent symptoms after erad-
ication of the parasite. An epidemiological study in Mich-
igan, USA[17] did not find any link between Giardia
infection and IBS, by correlating new Giardia cases with
prescriptions of three drugs (dicyclomine, tegaserod and
alosetron) used in IBS. In our study population any such
correlation would probably also not have been found as
patients were previously largely healthy, active young peo-
ple unaccustomed to taking drugs daily. Only a few had
abdominal complaints of a severity that any of these med-
ications would be considered.
In our study population we find a pattern of IBS-subtypes
with a high frequency of diarrhoeal symptoms and little
constipation. This agrees well with previous descriptions
of PI-IBS as a distinctive subgroup of IBS patients [18]. In
the general population in Norway a recent study with
4622 respondents showed that 10% in the relevant age
group fulfilled the IBS criteria and the pattern of subtypes
contrasts our findings with subtype A-IBS most com-
monly reported (53%), followed by similar prevalence of
the other two subtypes D-IBS (23%) and C-IBS (24%)
[19].
It is known that Giardia may cause prolonged symptoms
for several weeks after successful treatment due to second-
ary lactose intolerance [20]. In the present study we found
that many patients reported many different kinds of food
to worsen symptoms and that this persisted for years after
infection. A previous study has not found lactose-intoler-
ance to be factor in the aetiology of PI-IBS after bacterial
gastroenteritis[21]. Preliminary data from duodenal
lactase activity testing in newly referred patients with post-
giardiasis IBS at our hospital support this finding (unpub-
lished).
It is known that food-related gastrointestinal symptoms
are common in the general population and often coin-
cides with IBS. A previous study found that 51% of IBS-
patient considered that their symptoms were linked to
individual foods [8], and improvement following exclu-
sion diets have also been reported [22]. However, objec-
tive measurements methods, like skin prick test or
intestinal permeability have not been consistent with the
reported food-intolerance [23]. Outside of this study
many of the patients were referred to allergologic evalua-
tion with no specific findings. It thus seems that the food-
related symptoms seen in our patient population may be
intrinsically linked with the development of FGID.
The finding that around half the patients felt that physical
or mental stress influence their abdominal symptoms is
consistent with previous findings in patients with IBS of
all causes seeking medical care in Norway [9].
It remains speculative what may be the reason for devel-
opment of FGID after Giardia infection. Previous studies
have pointed to psychological factors, young age, and
severity and duration of the acute infection as factors
increasing the risk of FGID after bacterial gastroenteritis
[2,5]. We showed in a former study that a high frequency
of microscopic duodenal inflammation was found in our
study population when illness duration was 2–4 months,
indicating that the severity of host response may be a risk
factor for FGID in our population [11]. The initially high
frequency of duodenal microscopic inflammation nor-
malised within a year, but subtle low-grade inflammation,
not recognised by routine microscopy might be ongoing.
The particular genotype of Giardia responsible for the epi-
demic may also be a relevant risk factor in itself, as differ-
ent strains have been shown to differ in their ability to
induce small intestinal injury in rats [24]. The higher pro-
portion of females in our study population is probably
not indicating an increased risk, but rather a reflection of
more females contracting giardiasis during the epidemic,
probably as a consequence of higher water intake [25].
Host factors like age, no previous Giardia exposure or
infection, pre-existing intestinal microbiota, immuno-
logic and genetic predisposition may also play a role.
These will be interesting issues for further research.
All patients were treated with one or more courses of met-
ronidazole for their giardiasis. Although one study points
to a link between antibiotic treatment in general and
FGID[26], prolonged gastrointestinal symptoms is not
reported as a side effect of metronidazole. Although we
can not fully exclude this possibility, we think the Giardia
infection is a far more plausible cause of the later FGID
than its treatment.
A strength of this study is the relatively large number of
laboratory confirmed giardiasis cases who have been thor-
oughly investigated and followed for a long period of
time. However, it is therefore also important to note that
our data are drawn from a population likely to be the
more severely affected, and may not represent patients
with milder post-giardiasis abdominal symptoms. A con-
trol group presented with the same follow-up and ques-
tionnaire would have been desirable.
Patients were asked about previous abdominal com-
plaints retrospectively, one to two years after their Giardia
infection. Recall bias might influence the answers given.
Some caution should also be taken regarding the exclu-
sion of chronic giardiasis. Microscopy of three stool sam-
ples for Giardia cysts has a sensitivity of 85 – 90%[27].
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Our patient population had repeated series of Giardia neg-
ative faecal samples before referral and during the hospi-
tal workup, thus we consider the risk of low-grade chronic
infections to be very small.
Conclusion
Due to the subtype pattern consistent with PI-IBS, no
other discernable cause, and symptoms being elicited by a
symptomatic, laboratory confirmed Giardia infection, we
here document for the first time that the non-invasive pro-
tozoan pathogen Giardia lamblia may induce irritable
bowel syndrome and functional dyspepsia. Utilising the
unique setting of around 1300 laboratory confirmed Gia-
rdia cases, we are planning follow up studies of the fre-
quency and characteristics of FGID after Giardia infection
including population based approaches.
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Abstract  
Background: A Giardia outbreak was associated with development of post-infectious 
functional gastrointestinal disorders (PI-FGID) and chronic fatigue syndrome (PI-CFS). 
Markers of immune dysfunction have given conflicting results in CFS and FGID patient 
populations. The role of specific cellular immunity against the eliciting pathogen has not been 
assessed in PI-FGID or PI-CFS before. The aim of this study was to evaluate specific anti-
Giardia cellular immunity and markers of immune dysfunction in these two post-infectious 
syndromes. 
Methods: 48 patients, reporting chronic fatigue in a questionnaire study three years after the 
outbreak, were clinically evaluated five years after the outbreak and grouped according to 
Fukuda criteria for CFS (n=19) and idiopatic chronic fatigue (n=5) and Rome II criteria for 
FGIDs (n=54). 22 Giardia exposed non-fatigued individuals and 10 healthy unexposed 
individuals were recruited as controls. Peripheral blood lymphocyte subsets were analyzed 
by flow cytometry and Giardia specific immune responses were evaluated by flow cytometric 
and 3H-thymidine proliferation assays. 
Results: No differences in Giardia specific cellular immune responses were found between 
Giardia exposed controls and PI-FGID or PI-CFS patients. However, in peripheral blood we 
found significantly higher CD8 T-cell levels in PI-FGID, and significantly lower NK-cell levels 
in PI-CFS patients. Tendencies towards lower T-cell CD26 expression in PI-FGID and higher 
CD4 T-cell HLA-DR expression in PI-CFS were seen. 
Conclusion: Patients with PI-CFS and/or PI-FGID 5 years after Giardia lamblia infection 
showed alterations in NK-cell and CD8-cell populations indicating ongoing immune 
dysfunction, but specific anti-Giardia cellular immune responses were similar to Giardia
exposed no-fatigue controls. 
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INTRODUCTION 
Infection with the protozoan intestinal parasite Giardia lamblia is common in developing 
countries and is often seen in travellers returning from endemic areas [1]. It is also a frequent 
cause of waterborne outbreaks in industrialized countries, but it is generally regarded as an 
uncomplicated infection for which there is effective antibiotic treatment. Although long term 
abdominal symptoms following acute giardiasis have been observed by clinicians in 
individual patients for decades, post giardiasis functional gastrointestinal disorders (FGIDs) 
[2] and chronic fatigue have only recently been described [3] after a waterborne outbreak in 
Bergen in 2004 [4]. 
FGIDs are a group of disorders characterized by recurring or chronic gastrointestinal 
symptoms without an identifiable disease process [5]. Irritable bowel syndrome (IBS) and 
functional dyspepsia (FD) are the most well described FGIDs. Fatigue is a frequent symptom 
in FGID patients [6]. One study found that 14% of IBS patients also have chronic fatigue 
syndrome CFS [7], while six studies report that 51% (median) of (CFS) patients also have 
IBS. FGID and CFS share the characteristics of female preponderance, both are diagnoses 
relying on symptom criteria alone, and in many cases the onset is preceded by an acute 
infection [8]. Researchers of both FGID and CFS focus on the same pathophysiologic 
mechanisms [9, 10], but rarely control for this co-morbidity. 
When the onset of FGID or CFS is associated with an acute infection, it is often termed post-
infectious CFS (PI-CFS) [11, 12] or FGID (PI-FGID) [13] or in the case of IBS, post-infectious 
IBS (PI-IBS) [10, 14]. Until recently few studies separated between infection related onset 
and a less defined onset in these disorders. A meta-analysis of PI-IBS estimates that the risk 
of having IBS one year after an acute gastroenteritis is approximately sixfold [15].  
The role of specific cellular immunity against the eliciting microbe has not been evaluated in 
PI-CFS or PI-FGID. The present study, performed in a well-defined group of patients with 
clinically observed post-infectious FGID and CFS after a common eliciting infection, was 
done with two main aims; 
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1. to evaluate a wide selection of immune dysfunction markers reported in lymphocyte 
subsets and 
2. to examine the possible role of host specific cellular immunity against the culprit infectious 
agent G. lamblia. 
METHODS 
Study population 
In 2007, three years after the outbreak, all 1252 persons with microscopy confirmed Giardia 
infection during the outbreak received a questionnaire regarding fatigue and abdominal 
complaints [3]. Five years after the outbreak 253 persons reporting chronic fatigue in this 
study received a mailed invitation, and 53 of these chose to participate in the present study, 
see figure 1. These patients went through a clinical evaluation and were screened with a 
battery of routine blood tests and a magnetic resonance imaging (MRI) brain scan. 
Additionally, 22 sex and age matched controls were recruited among the respondents, and 
10 healthy Giardia unexposed healthy controls were also included. All were HIV negative and 
were not taking immunomodulatory or antibiotic medications. Written consent was obtained 
from the participants. The study was approved by the Regional Committee for Ethics in 
Medical Research and the Norwegian Social Society Data Services in Bergen, Norway. 
Sampling 
Patient and control blood samples for routine exclusion of other diseases and for this study 
were taken between 08am and 09am after overnight fast and analyzed in parallel during the 
same period. Fecal samples were screened with microscopic examination and 18S PCR [16] 
of feces to rule out chronic giardiasis. 
5
Questionnaires 
Both patients and controls completed a Rome II questionnaire [5] enabling the classification 
of abdominal symptoms into IBS and FD or other FGID. An abdominal symptom scoring form 
was used to quantify abdominal symptoms [17]. Questions about abdominal complaints 
before the Giardia infection enabled identification of post-infectious FGIDs. 
To evaluate severity of fatigue, patients and controls also completed the Fatigue 
Questionnaire [18], a validated set of 11 questions addressing different aspects of fatigue.  
FGID and fatigue categorization 
Patients and controls were classified according to the Rome II questionnaire with regard to 
FGID. Patients were clinically evaluated by specialists in internal medicine, psychiatry and 
neurology and were classified as PI-CFS or PI-idiopathic chronic fatigue (ICF) according to 
the 1994 Fukuda criteria [19], or as fatigue most plausibly due to other causes, or as 
recovered. In the PI-CFS group one patient was diagnosed with dysthymia and one with 
agoraphobia and in the PI-ICF group there were no psychiatric comorbidity. Patients who 
had co-morbidities that could plausibly explain their fatigue were termed “fatigue other 
cause”. Some individuals had fully recovered from the fatigue, which they had reported in the 
questionnaire two years previously, and were termed “fatigue recovered”. 
Three different categories of patient groups were used in analyses of the relative importance 
of CFS and FGID co-morbidity on immunological variables; a fatigue category, a FGID 
category and a combined category (Table 1). In the fatigue category, exploratory analyses of 
lymphocyte subsets in the small group of patients with PI-ICF (n=5) showed similarities with 
the PI-CFS group. The two groups were therefore analyzed together unless otherwise clearly 
stated in the text. 
Regarding the FGID division, a number of patients’ symptoms did not match either the FD or 
the IBS criteria. These would qualify for the less well-defined FGIDs like functional bloating, 
functional diarrhea, functional abdominal pain and unspecified functional bowel disorder. For 
simplicity they were termed “other FGID”, and in some analyses they were grouped together 
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with the IBS and FD groups forming an “all FGIDs” group. Three individuals had both FD and 
IBS and were grouped as IBS in the analysis. Some exposed non-fatigued controls also had 
FGID and were put together with the FGID group in some analyses. Seven of the participants 
had FGID-like abdominal symptoms also before their Giardia infection. In some analyses 
these were taken out in order to analyze PI-IBS and PI-FGID specifically. 
In the analyses we also defined a combined category with one group of participants who had 
both FGID and CFS/ICF, one group who had FGID only, and one group with fatigue other 
cause with or without fatigue. These groups were compared to each other and to healthy 
controls with neither FGID nor fatigue. 
Lymphocyte quantification 
Lymphocyte subpopulation quantification was performed using the BDMultitest6-colorTBNK 
kit with BD Trucount Tubes for relative and absolute concentration determination (BD 
Biosciences, San Jose, CA, USA). The samples were prepared according to the 
manufacturer’s instructions and analyzed on a BD Canto II flow cytometer (BD Biosciences). 
PBMC acquisition and immunophenotyping 
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient separation 
from BD Vacutainer Na-citrate CPT tubes (BD, Franklin Lakes, NJ, USA). After harvesting, 
the PBMC were washed twice in PBS and were immunophenotyped as follows, or were 
cultured using the specific immunity assays described below. Cell suspensions (50µl) were 
stained 30 minutes in the dark using combinations of the following optimally titrated 
fluorescent dye-conjugated antibodies anti-CD8a-FITC, anti-CD27-FITC, anti-CD26-PE, anti-
7-PE, anti-CD45RO-PE, anti-CD4-PerCP/Cy5.5, anti-CD56-PerCP-Cy5.5, anti-CD19-
PE/Cy-7, anti-CD45RA-PerCP-Cy5.5, anti-HLADR-PE/Cy7, anti-CD25-PE/Cy7 (BioLegend, 
SanDiego, CA, USA), anti-CD3-ECD (Beckman Coulter, Brea, CA, USA) and anti-CD127-
PerCP-Cy5.5 (eBioScience, SanDiego, CA, USA). Appropriate isotype controls from the 
same manufacturer were used at equal concentrations. After staining, cells were washed 
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once, resuspended in PBS-paraformaldehyde solution (1%) and analyzed the same day 
using a Beckman Coulter Cytomics FC 500 MPL flow cytometer. In a typical acquisition 
7x104 lymphocytes (min 2.3 x104, max 1.7 x105) were collected. The collected data were 
analyzed with FlowJo 7.6 software (Tree Star Inc, Ashland, OR, USA). 
Cellular immunity assays 
PBMC were cultured for 6 days in the presence of control antigens and Giardia antigens 
obtained from the supernatant of sonicated Giardia genotype A and B reference strains 
trophozoites at a protein concentration of 10 µg/ml. Proliferative responses were measured in 
stimulated cultured cells after pulsing with 3H-thymidine after 5 days, harvesting 18 hours 
later and analyzing incorporated radioactivity. T-cell activation markers were analysed by 
flow cytometric measurement of T-cell subsets with HLA-DR and CD45RO or CD25 and 
CD26 after 6 days in culture. Details of culture, control antigens and analyses are described 
elsewhere (Hanevik et al. 2011, in press). 
Statistical analysis 
Unless otherwise stated the data are presented as mean (standard deviation (SD)). Chi-
squared tests were used for categorical comparisons between groups. Linear regression 
analysis was used for correlation between symptom scores and lymphocyte data. The 
significance level was p=0.05. Lymphocyte subset data and stimulation indices were 
analyzed using the Kruskal-Wallis test for all groups and then Mann Whitney U test to 
compare two groups. Due to multiple comparisons in lymphocyte subset analyses and a high 
number of variables, we chose a nominal significance level of 0.01 for subgroup 
comparisons. PASW 18 (SPSS Inc, Chicago, Ill, USA) was used for statistical analysis. 
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RESULTS 
Data from 48 patients (mean age 42.3 years (11.5) range19-68, females 79%), 22 exposed 
controls (mean age 39.8 (10.5) range 26 -66, females 73%) and 10 unexposed controls 
(mean age 43.3 (14.3) range 22-63, females 76%) were analyzed in this study. All 
participated in lymphocyte quantification, but for logistical reasons not all patients and 
controls has all immunological tests done, numbers given in Figure 1. The numbers of 
patients and controls allocated into the fatigue, FGID and combined categories are shown in 
Table 1. There were no significant differences in age and male/female distributions between 
the groups in each category. 
Lymphocyte quantification 
Peripheral blood lymphocyte subset results for the three study categories are shown in Table 
2. We found the CD4:CD8 ratio to be reduced and total CD8 T-cells to be increased in the 
FGID groups compared to the no-FGID control group. The PI-CFS/ICF patients had a lower 
percentage of natural killer (NK)-cells than the no fatigue control group (p=0.006). 
The same pattern was seen in the combined category, with elevated CD8 in both the group 
with FGID&CFS/ICF and the FGID only group, and also a strong trend for differences in NK-
cell percentage (p=0.044) and concentration (p=0.036) between these groups. The 
percentage and concentrations of CD3 and CD4 T-cells and CD19 B-cells were similar in all 
groups tested. A significant correlation was found between the fatigue and abdominal 
symptoms scores (R=0.421, p<0.001) and both correlated significantly with NK-cell levels 
(Figure 2) but not with CD8 T-cell levels. 
Immunophenotyping 
CD4 and CD8 T-cells were analysed for expression of activation markers HLA-DR, CD25, 
CD26, and CD27 and CD45RO. CD56+ NK-cells were analysed for CD26. CD19+ B-cells 
were analysed for activation markers CD25, CD26 and CD27. Additionally, we analysed 
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percentage of gut-homing integrin 7 positive T-cells, B-cells and CD4+CD25++CD127neg T-
regulatory cells.  
T-cells expressing activation markers HLA-DR and CD26 showed some differences between 
controls and patient groups. In particular, the percentage HLA-DR positive CD4 T-cells was 
higher in the FGID&CFS/ICF group (6.2 (1.9)) compared to the “no FGID/no fatigue” group 
(4.9 (2.2)) (p=0.02) and was significantly lower (p=0.002) in the recovered group compared 
to the PI-CFS group, see selected subset data given in Supplementary table 1. 
The percentage of CD26 positive CD3 T-cells in the “all FGID” group was decreased 
(p=0.03) compared to the control group without FGID. The same difference was seen again 
in the combined category with 83.7% (6.2) CD26 positive CD3 T-cells in the “FGID, no 
fatigue” group and 77.1% (8.8) in the “no FGID/no fatigue” group (p=0.01).  
We did not find any significant differences along the FGID or CFS categories regarding the 
percentage of CD56dim or CD56bright NK-cells or for CD26 positive subpopulations of these 
NK-cell subsets. Nor did we find any significant differences between groups for activation 
markers CD25, CD26 and CD27 in CD19 positive B-cells or in the percentage of gut-homing 
integrin 7 positive T-cells, B-cells or CD4+CD25++CD127- Treg cells. 
Cellular immune response 
Both the proliferation assay and flow cytometric markers showed a significant difference in 
Giardia specific cellular immunity between the patients and exposed controls compared to 
the unexposed controls. However, neither assay showed any significant differences between 
exposed controls and patients with post-giardiasis FGID or CFS. Data from proliferation 
assay and one flow assay for the two human infecting Giardia genotypes and control 
antigens are shown in Table 3. In additional assays and when analyzing CD4 and CD8 T-cell 
subsets separately we did not identify significant differences either (data not shown). 
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DISCUSSION 
In this study we classified patients and controls with FGID according to Rome II criteria and 
by the Fukuda CDC criteria for CFS and ICF regarding fatigue. A range of peripheral blood 
lymphocyte subsets reported to be altered in CFS and FGID were analyzed and the specific 
cellular immune response against Giardia was investigated. 
CD8 T-cells and CD4:CD8 ratio 
In literature regarding CD4 and CD8 T-cell subsets and ratio in FGID we found two studies 
which did not find differences in T-cell subsets [20, 21] and two studies with lowered 
CD4/CD8 ratio in IBS patients; one due to high total CD8 cells [22] and one due to low CD4 
cells [23]. While CD4 and CD8 T-cell numbers and percentages may fluctuate considerably 
within an individual over time, the CD4:CD8 ratio is found to be relatively stable [24]. We 
found the CD4:CD8 ratio to be low due to increased CD8 T-cell numbers in our PI-FGID 
study population. Similar peripheral blood T-cell patterns are reported in patients suffering 
from a number of viral diseases like mononucleosis, dengue, RSV and cytomegalovirus 
infection and herpes simplex recrudescence as well as in chronic toxoplasmosis infection 
[24, 25]. A low grade ongoing immune response against reactivated viruses is a hypothesis 
of CFS morbidity [26]. However, in our patient population this pattern was seen in PI-FGID 
and not to PI-CFS. 
NK-cells in FGID and CFS 
Peripheral blood CD56+ NK-cells levels in IBS patients were similar to healthy controls in two 
studies [21, 27]. A post-prandial decrease in NK-cells in IBS patients relative to controls has 
also been described [28]. 
The majority of studies of NK-cells in heterogeneous CFS populations have not found 
differences in NK-cell levels [29, 30]. Two studies have found significantly reduced NK-cell 
levels in both PI-CFS and non-PI-CFS patients [12, 31]. In one of these non-PI-CFS patients 
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had significantly lower NK-cells levels than PI-CFS patients [31], and NK-cell levels returned 
to normal after successful recovery in the PI-CFS group [32]. In our study, fatigue scores 
correlated with NK-cell levels, and the patients who had recovered from chronic fatigue 
showed NK-cell levels comparable to the non-fatigue control group. These data suggest that 
decreased NK- cells are associated with ongoing fatigue in PI-CFS. 
Activation markers and subsets 
HLA-DR expressing CD8 T-cells in CFS have been increased in three published studies, 
while six other studies did not find a difference [29]. One study in IBS patients has shown 
elevated levels of gut homing T-cells expressing HLA-DR [20]. In the present study we found 
a trend towards increased HLA-DR expression in CD4 T-cells in the combined FGID & 
CFS/ICF group compared to controls and a significant reduction in the small group recovered 
from fatigue. 
We could not replicate the elevated levels of CD26 expression in T and NK-cells as a robust 
marker of CFS reported by Fletcher et al [33]. Instead, there was a strong tendency towards 
lower CD26+ T-cells in FGID patients. 
A study in CFS patients recently reported higher levels of CD4+CD25++FoxP3+ cells [30]. We 
found no difference in regulatory T-cells as measured by CD4+CD25++CD127- cells, similar to 
a finding done in FGID patients [34]. 
Specific immune response 
Analysis of specific humoral immunity in PI-CFS after parvovirus B19 infection did not identify 
any distinguishing pattern [35]. Pathogen specific cellular immunity against the infection 
eliciting PI-CFS and PI-FGID has to our knowledge not been investigated before. The similar 
levels of long term cellular immunity against G. lamblia found in symptomatic patients and 
the exposed recovered control group indicates that T-cell dependent host response towards 
the eliciting organism is not a risk factor for development of PI-FGID or PI-IBS. This does not 
exclude the possibility of an initially stronger, qualitatively different or prolonged immune 
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response leading to the immune dysfunction markers seen by elevated CD8 and lowered 
NK-cell levels in our patient group. 
Cautionary remarks 
NK-cells are influenced by sleep and depression [36]. We did not control for poor sleep, but 
no patients in the CFS/ICF group had clinical depression. NK-cells are also known to 
fluctuate considerably with exercise, but the resting immune function evaluated in this study, 
is not very different in athletes compared to non-athletes [37]. The cytotoxic activity of NK-
cell has been more consistently decreased in CFS studies, but may be a bystander effect as 
it has been shown to be decreased in chronic stress like unemployment, while NK-cell 
concentration was not [38]. 
Conclusion 
Using two different methods for assessing the host cellular immune response against Giardia
we found no difference between asymptomatic Giardia exposed controls and patients with 
FGID or CFS. In the patients who developed PI-FGID and PI-CFS after giardiasis, we found 
significantly increased CD8 T-cells in patients with FGID and reduced levels of NK-cells in 
CFS patients. There was a close correlation between fatigue and abdominal symptoms in the 
study population and severity of symptom scores correlated with NK-cell levels. The findings 
support an ongoing immune dysfunction that does not seem to be associated with an altered 
specific immune response to Giardia. 
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Table 1.  Sex ratio and mean age in the different clinical groups after allocation of patients 
and controls according to Rome II FGID groups [5] and Fukuda CDC criteria [19] for the 
three analysis categories used in the present study. Subgroups of interest within each group 
are indicated by indents. 























   no-fatigue 40.9 (11.7) 72 32 0 22 10
   CFS 45.5 (9.1) 79 19 19 0 0
   ICF 37.8 (8.9) 80 5 5 0 0
   Fatigue other cause 45.5 (15.2) 100 12 12 0 0
   Fatigue recovered 36.0 (9.6) 58 12 12 0 0
FGID category 
   no-FGID 41.8 (13.2) 78 26 5 11 10
   All FGID 41.4 (10.8) 76 54 43 11 0
            PI-FGID 40.8 (10.2) 76 45 36 9 0
       IBS  41.7 (10.4) 80 30 27 3 0
            PI-IBS 40.4 (10.4) 79 24 22 2 0
       Other FGID 41.1 (11.5) 71 24 16 8 0
Combined category 
   no-FGID/no-fatigue 39.9 (12.5) 74 23 2 11 10
   FGID&CFS/ICF 44.3 (9.4) 78 23 23 0 0
   CFS, no FGID 35.0 100 1 1 0 0
   FGID, no fatigue 39.1 (10.1) 62 21 10 11 0
   Fatigue other cause 
   w/wo FGID 45.5 (11.5) 100 12 12 0 0
Abbreviations: CFS: chronic fatigue syndrome, FGID: functional gastrointestinal disorder, ICF: 












































































































































































































































































































































































































































































































































































































































































































































































































   





   
















































































































































































































































































































































































































































































Table 3. Immune responses against Giardia and control antigens as measured by 3H-
thymidine proliferation assay and CD25CD26 positive lymphocytes measured by flow-
cytometry in the exposed controls and exposed patients with PI-CFS and PI-FGID  and 
“fatigue other cause” groups, omitting individuals with FGID before the outbreak (n=3) and 
CFS without FGID (n=1). All responses expressed as median stimulation indicies (standard 

























   Giardia A cytosolic fraction 17.4 (11.6) 15.3 (19.9) 10.0 (51.6) 20.3 (10.9) 3.5 (6.2)*
   Giardia B cytosolic fraction 14.2 (16.7) 13.3 (15.3) 9.3 (31.8) 23.3 (13.4) 3.5 (4.7)*
   LPS S.typhi 1g/ml 15.0 (11.6) 14.4 (31.2) 21.9 (22.0) 38.2 (34.3) 17.7 (10.5)
   Tuberculin (PPD) 10g/ml 33.1 (42.2) 34.0 (47.5) 30.2 (23.4) 54.9 (84.5) 27.7 (27.0)
   aCD3aCD28 (pos ctr)  76.2 (37.6) 51.4 (33.0) 51.8 (54.2) 52.7 (44.1) 60.1 (39.8)
Flow cytometric assay      
   Giardia A cytosolic fraction 112 (238) 53.1 (83.1) 68.5 (64.7) 43.3 (33.4) 12.5 (98.5)*
   Giardia B cytosolic fraction 34.7 (133) 34.0 (50.4) 28.5 (29.6) 26.9 (27.9) 11.8 (19.2)*
   LPS S.typhi 1g/ml 110 (388) 40.0 (96.8)) 46.4 (55.7) 36.9 (24.4) 32.8 (128)
   Tuberculin (PPD) 10g/ml 70.9 (175) 83.1 (120) 85.4 (77.4) 43.0 (56.2) 61.7 (113)
* Statistical difference between the combined exposed group and unexposed group with p-
values <0.001 for the proliferation assay and <0.01 for the flow cytometry assay by the 






































































































































































































































































































































































































































































































































































































































































































































































































































































































   





   





























































   
   

























































































































































































































































































































































































Figure 1. Study recruitment base and participants. 
Participants were recruited based on a mailed questionnaire study  regarding fatigue [18] and 
abdominal complaints [39] to all individuals with outbreak related laboratory confirmed 
giardiasis [3]. Five years after the outbreak, patients who reported chronic fatigue in this 
questionnaire were invited to participate in a thorough clinical evaluation and screening. Fifty 
three individuals agreed to participate. Five patients were excluded from this study after 
evaluation. Two control groups were recruited; 22 individuals with normal score (=11) in the 
questionnaire three years after, and 10 healthy individuals not affected by the outbreak 
(unexposed controls) and without particular abdominal symptoms or fatigue.
Figure 2. NK-cell levels and symptoms correlations 
Correlation plots between the percentage of peripheral blood CD16CD56 NK-cells and 
fatigue symptom score (A) as recorded by the fatigue questionnaire [18] and total abdominal 
symptoms score (B) (including the six symptoms nausea, early satiety, bloating, abdominal 
pain, constipation and diarrhoea, where patients graded their symptoms on an ordinal scale 












Appendix I  
Rome II - Functional gastrointestinal disorders  
A. Esophageal disorders A1. Globus 
A2. Rumination syndrome 
A3. Functional chest pain of presumed  
      esophageal origin 
A4. Functional heartburn 
A5. Functional dysphagia 
A6. Unspecified functional esophageal disorder 
B. Gastroduodenal disorders B1. Functional dyspepsia 
   B1a. Ulcer-like dyspepsia 
   B1b. Dysmotility-like dyspepsia 
   B1c. Unspecified (non-specific) dyspepsia 
B2. Aerophagia 
B3. Functional vomiting 
C. Bowel disorders C1. Irritable bowel syndrome 
C2. Functional abdominal bloating 
C3. Functional constipation 
C4. Functional diarrhea 
C5. Unspecified functional bowel disorder 
D. Functional abdominal pain D1. Functional abdominal pain syndrome 
D2. Unspecified functional abdominal pain 
E. Biliary disorders E1. Gall bladder dysfunction 
E2. Sphincter of Oddi dysfunction 
F. Anorectal disorders F1. Functional fecal incontinence 
F2. Functional anorectal pain 
   F2a. Levator ani syndrome 
   F2b. Proctalgia fugax 
F3. Pelvic floor dyssynergia 
G. Functional pediatric G1. Vomiting 
     disorders    G1a. Infant regurgitation 
   G1b. Infant rumination syndrome 
   G1c. Cyclic vomiting syndrome 
G2. Abdominal pain 
   G2a. Functional dyspepsia 
   G2b. Irritable bowel syndrome 
   G2c. Functional abdominal pain 
   G2d. Abdominal migraine 
   G2e. Aerophagia 
G3. Functional diarrhea 
G4. Disorders of defecation 
   G4a. Infant dyschezia 
   G4b. Functional constipation 
   G4c. Functional fecal retention 
   G4d. Non-retentive fecal soiling 
Modified from Drossman DA. The functional gastrointestinal disorders and the Rome II 
process. Gut 1999 

